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ABSTRACT
The Effects of Aging on Skeletal Muscle AMPK Activation and an Analysis
of Chronic AICAR Treatment on the Aging Phenotype
Shalene E. Hardman
Department of Physiology and Developmental Biology, BYU
Doctor of Philosophy
AMP-activated protein kinase (AMPK), a metabolic regulator, acts in opposition to many
of the effects of aging and may provide insights into the development of sarcopenia. However,
the effect of aging on AMPK activation is unclear. The purpose of this dissertation was to: 1)
clarify the controversy concerning the activation of AMPK in response to endurance-like
exercise in aged skeletal muscle; 2) address mechanisms for the age-associated alterations in
AMPK activation; and 3) address the known benefits of chronic AICAR treatment in aged
skeletal muscle.
First, to clarify the effect of age on AMPK activation, young adult (YA) (8 mo.) and old
(O) (30 mo.) male Fischer344 x Brown Norway F1 hybrid rats received an in situ bout of
endurance-type contractions produced via electrical stimulation of the sciatic nerve (STIM).
AMPK activation was attenuated in aging muscle as demonstrated by decreased AMPKα
phosphorylation and AMPKα2 protein content and activity in O vs. YA muscle after STIM. In
contrast, AMPKα1 content was greater in O vs. YA muscle, and α1 activity increased with STIM
in O but not YA muscles.
Second, the effect of age on the AMPK heterotrimer composition and nuclear localization
was assessed as mechanisms for the altered AMPK activation. The AMPK heterotrimer
composition was altered in aging skeletal muscle with lower AMPKγ2 and γ3 content and
decreased association of AMPKγ3 with AMPKα1 and α2. Furthermore, activation of AMPK is
known to increase translocation of AMPK to the nucleus in YA muscle; however, translocation
of phosphorylated AMPK, AMPKα2, and AMPKγ3 were impaired in the aging rat muscle after
STIM.
Finally, chronic activation of AMPK with 5’-aminoimidazole-4-carboxamide-1-β-Dribofuranoside (AICAR) is known to increase mitochondrial content, activate autophagy, and
repress protein synthesis; pathways that are altered with aging. The known benefits of chronic
AICAR treatment were assessed in YA (5 mo.) and O (23 mo.) male C57Bl/6 mice. Mice were
treadmill tested prior to and after one month of AICAR treatment. In vitro muscle contractions
were performed following AICAR treatment. AICAR treatment improved the O mice treadmill
endurance and the YA mice rate of fatigue and recovery. Additionally, AICAR increased citrate
synthase activity, decreased SQSTM1/p62 protein content , and decreased Myf6 protein content
in both the YA and O mice suggesting increased mitochondrial activity, autophagy, and
decreased muscle regeneration. Therefore, chronic AICAR treatment may alter metabolic
pathways to improve the exercise response in both YA and O mice.
Keywords: AMPK, aging, skeletal muscle, heterotrimer, AICAR, metabolism
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CHAPTER 1: Review of the Literature
Metabolic Pathways are Altered with Sarcopenia
Sarcopenia, or age-related skeletal muscle atrophy, affects 20-50% of adults over the age
of 60 years (Berger & Doherty, 2010b) and contributes to the decline of muscle mass and
strength that leads to frailty with aging (Thompson, 1994; Verdijk et al., 2010a). Age-related
alterations in muscle fibers lead to decreased maximal isometric force during contraction and
result in muscle weakness and frailty (Thompson, 1994). Sarcopenia and frailty significantly
impact the quality of life of elderly individuals. Furthermore, frailty in the elderly is an indicator
of an increased risk for disease, functional dependency, and/or death (Evans et al., 2010). The
increased risks associated with sarcopenia may be attributed to alterations in skeletal muscle
metabolism and function as a result of aging.
Impaired skeletal muscle metabolism associated with aging has been linked to an
increased number of dysfunctional mitochondria. As a result of aging, mitochondria become
enlarged with structural deterioration of the inner membrane along with an increased lack of
polarity (Terman et al., 2006a). These alterations in the mitochondrial structure result in
decreased functionality of the mitochondria. Additionally, the mitochondrial electron transport
chain complexes show decreased activity with age, limiting the amount of adenosine
triphosphate (ATP) generation (Kumaran et al., 2004b). Generation of ATP is further
diminished through an overall decrease in the mRNA transcripts that encode mitochondrial
proteins, further suppressing the oxidative capacity of the mitochondria (Short et al., 2005;
Menshikova et al., 2006). The decreased oxidative capacity of the mitochondria decreases
skeletal muscle metabolism and function, contributing to the muscle wasting associated with
sarcopenia.
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The mitochondrial impairment in aged tissue leads to decreased rates of fatty acid
oxidation. Elderly individuals show a 25-35% decrease in fatty acid oxidation following exercise
in comparison to young adults (Coggan et al., 1992b; Sial et al., 1996). Inversely correlated to
the decrease in fatty acid oxidation, elderly individuals have increased triglyceride levels (Park et
al., 2006). As a result, the elderly show increased deposition of fatty acids in the liver, skeletal
muscle, and pancreas (Slawik & Vidal-Puig, 2006) which often coincides with a change of body
composition leading to increased body fat mass or obesity (Calles-Escandón & Poehlman, 1997).
The increased number of dysfunctional mitochondria may further be amplified by the
decreased rate of autophagy associated with aging. Autophagic vacuoles regulate the turnover
rate of mitochondria and other organelles thereby slowing the accumulation of damaged cellular
components (Pfeifer, 1978). Increasing age is associated with fewer and smaller autophagic
vacuoles with decreased lysosome interaction (Del Roso et al., 2003). The inefficiency of
autophagic vacuoles with age results in an increased accumulation of damaged organelles.
Furthermore, the age-related decrease and delay in autophagic vacuoles results in decreased
binding of substrate proteins along with decreased lysosomal degradation rates (Cuervo & Dice,
2000). Therefore, old age results in an accumulation of damaged organelles and oxidative stress
along with alterations in protein turnover, further contributing to the effects of sarcopenia
(Combaret et al., 2009).
Age further results in deregulation of protein homeostasis by not only altering protein
degradation but also protein synthesis. Total body protein decreases in elderly individuals by
14% with the majority of the protein loss being attributed to a decrease in muscle protein content
(Cohn et al., 1980). The decrease in muscle protein content is correlated to a 45% decrease in
skeletal muscle mass with sarcopenia (Cohn et al., 1980). Skeletal muscle contraction and amino

2

acid supplementation, both known to increase protein synthesis, have a reduced effect in the
elderly compared to younger individuals (Dardevet et al., 2000; Fry et al., 2011). Therefore,
elderly individuals have an impaired response to stimuli known to increase the rate of protein
synthesis, which may contribute to the symptoms of sarcopenia.
AMPK is a Metabolic Regulator
Adenosine monophosphate (AMP) -activated protein kinase (AMPK), a metabolic
regulator, acts in opposition to many of the effects of aging and may provide insight into the
effects of aging. AMPK is a heterotrimeric protein composed of a catalytic α subunit along with
regulatory β and γ subunits (Davies et al., 1994; Woods et al., 1996a; Cheung et al., 2000). The
α and β subunits each have two distinct isoforms referred to as α1 and α2 or β1 and β2
respectively (Salt et al., 1998b). The γ subunit has three distinct isoforms referred to as γ1, γ2,
and γ3 (Thornton et al., 1998). In rat skeletal muscle, the α2 and β2 isoforms are most commonly
expressed; however, both the β1 and β2 isoforms play a role in AMPK α2 activation (Thornton
et al., 1998). Liver kinase B1 (LKB1), a serine /threonine kinase, phosphorylates the α subunit
on the threonine 172 residue of AMPK to activate AMPK in skeletal muscle in response to
endurance exercise (Hawley et al., 1996; Winder & Thomson, 2007). In addition, endurance
exercise creates an energy-challenged state, which increases the amount of AMP in comparison
to ATP (Sakamoto et al., 2005; Winder et al., 2006). AMP binds to the gamma subunit of
AMPK to make AMPK a better substrate for LKB1 (Hawley et al., 1995; Hawley et al., 1996;
Scott et al., 2007) and a worse substrate for Protein phosphatase 2C (PP2C), an AMPK
phosphatase (Davies et al., 1995a; Marley et al., 1996). AMP additionally induces a
conformational change in AMPK to further induce allosteric activation of AMPK (Hawley et al.,
1995; Scott et al., 2004; Witczak et al., 2008b). The γ subunits regulate the AMP dependence of
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the AMPK heterotrimer. γ2 complexes have a higher AMP dependence than γ1 subunits, which
have a higher AMP dependence than γ3 subunits (Cheung et al., 2000).
Increased activation of AMPK is associated with increased translocation of AMPK to the
nucleus. AMP-regulated allosteric activation of AMPK increases nuclear localization of the
AMPKα2 isoform (Salt et al., 1998b; McGee et al., 2003). Translocation of AMPKα2 from the
cytosol to the nucleus allows AMPK to regulate gene expression (Witczak et al., 2008b). The β1
isoform is also localized to the nucleus through myristoylation and phosphorylation (Warden et
al., 2001a). The γ1 isoform further demonstrates preferential nuclear localization compared to
the other two isoforms (Turnley et al., 1999b). Thus, when localized to the nucleus, AMPK may
regulate cell function by altering gene expression, but when localized to the cytoplasm it may
have direct effects on metabolism (e.g. by directly promoting fatty acid oxidation (Foretz et al.,
1998b), increasing glucose transport (Foretz et al., 1998b), autophagy (Meley et al., 2006) and
inhibiting processes that consume ATP such as lipogenesis (Foretz et al., 1998b), protein
synthesis (Bolster et al., 2002; Reiter et al., 2005) and cholesterol synthesis (Henin et al., 1995)).
AICAR is a Pharmacological Activator of AMPK
AICAR, or 5’-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, is a
pharmacological activator of AMPK. AICAR increases the accumulation of 5-amino-4imidazole-carboxamide ribotide (ZMP) in the cell in a dose-dependent manner (Sabina et al.,
1985; Sullivan et al., 1994). ZMP mimics 5’-AMP to increase AMPK activation through both
allosteric activation and promotion of phosphorylation of AMPK (Sullivan et al., 1994; Corton et
al., 1995).
AICAR is sufficient to activate AMPK in skeletal muscle similar to the activation
response of exercise and muscle contraction (Merrill et al., 1997). Acute AICAR treatment in
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skeletal muscle increases fatty acid oxidation (Merrill et al., 1997), glucose uptake (Merrill et al.,
1997) autophagy (Sanchez et al., 2012) and protein synthesis(Bolster et al., 2002). Furthermore,
chronic AICAR treatment increases mitochondrial gene expression and enzyme activity (Holmes
et al., 1999; Winder et al., 2000; Zhou et al., 2000; Narkar et al., 2008) and increases running
endurance (Narkar et al., 2008). Therefore, it has been proposed that AICAR treatment may be
sufficient to both enhance and/or compensate for the exercise training response (Narkar et al.,
2008).
The Effect of Age on AMPK Activation is Controversial
The effect of aging on AMPK activation and composition is not well understood. Some
studies have supported the hypothesis that AMPK is hyperactivated in aging skeletal muscle.
Aging is associated with decreased mitochondrial function, which will limit the availability of
ATP and increase the ratio of AMP to ATP under cell stress conditions such as exercise. An
increased ratio of AMP to ATP suggests that aging would result in increased activation levels of
AMPK in response to exercise. Muscle wasting is increased in old age, which may be correlated
to a decrease in muscle fibers and protein synthesis (Thompson, 1994; D'Antona & Nisoli,
2010). Activation of AMPK down regulates protein synthesis by inhibiting activation of the
mTOR pathway (Bolster et al., 2002). Additionally, activation of the mTOR pathway after in situ
muscle contraction is attenuated more in aged rats compared to young rats (Parkington et al.,
2004), resulting in a greater inhibition of protein synthesis. Since AMPK inhibits protein
synthesis through inhibiting the mTOR pathway, the muscle wasting that occurs in response to
aging further supports a possible increase in the activation levels of AMPK.
The hypothesis that AMPK activation levels increase in correlation with the aging
process has been supported in studies that analyzed AMPK levels in response to resistance-type

5

training. Thomson et al. (Thomson & Gordon, 2005) showed that in response to overloadinduced hypertrophy, aged skeletal muscle show a decreased percent hypertrophy in fast-twitch
muscle but higher activation levels of AMPK than young skeletal muscle. Increased levels of
AMPK activation in aged skeletal muscle was further shown by Thomson et al. (Thomson et al.,
2009) using high-frequency electrical stimulation (HFES) of the sciatic nerve to mimic
resistance-type muscle contractions. HFES in aged skeletal muscle resulted in hyperactivation of
AMPK in aged fast-twitch muscle along with increased AMPKα2 activity. Thomson et al.
further showed that pharmacological activation of AMPK using AICAR increased AMPK
activation but showed no significant difference in activation with age. The increased levels of
AMPK activation in response to resistance exercise as a result of aging in rats observed by
Thomson et al. are similar to results observed in humans by Drummond et al. (Drummond et al.,
2008). In response to resistance exercise, elderly individuals showed increased AMPKα
phosphorylation of Thr172 in contrast to younger individuals. Therefore, resistance exercise
appears to result in a greater increase in AMPK activation in aged skeletal muscle in comparison
to young skeletal muscle.
The effects of aging on metabolic pathways acts in opposition to AMPK activation;
therefore, it may alternatively be hypothesized that decreased AMPK activity might contribute to
age-related muscle metabolic dysfunction. In skeletal muscle, AMPK promotes the formation of
oxidative fibers by increasing the transformation of type IIb to type IIa/x muscle fibers (Röckl et
al., 2007). In contrast, older individuals show increased amounts of type I slow-twitch muscle
fibers as opposed to type IIa fast twitch muscle fibers (Thompson, 1994). AMPK also promotes
mitochondrial biogenesis to increase muscle mitochondria density (Bergeron et al., 2001b) and
therefore ATP production. AMPK activation results in an increased expression of peroxisome
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proliferator-activated receptor-gamma coactivator-1alpha (PGC-1α) (Garcia-Roves et al., 2008)
which regulates the expression of mitochondrial proteins through peroxisome proliferatoractivated receptor alpha (PPARα) (Vega et al., 2000), increasing mitochondrial biogenesis.
AMPK activation further increases mitochondrial turnover rate by allowing the induction of
autophagy (Pfeifer, 1978; Sanchez et al., 2012). Age alters expression of proteins that regulate
autophagy and proteosomal degradation, namely a decrease in autophagy-related gene 7 (Atg7)
expression and an increase in p62/SQSTM1 expression (Cui et al., 2012). AMPK acts in
opposition to aging by increasing autophagy. AMPK binds to ULK1 (UNC-51-like kinase) (the
mammalian homologue of yeast Atg1 that works concertedly with Atg7) to block the inhibition
of ULK1 by mTOR (Lee et al., 2010; Sanchez et al., 2012). Binding of AMPK to ULK1 allows
the induction of autophagy in skeletal muscle. The role AMPK plays in opposition to the effects
of aging suggests that there is a decrease in AMPK activity as a result of aging.
In support of this hypothesis, Reznick et al. (Reznick et al., 2007b) demonstrated that at
rest, phosphorylated AMPK was not different between young adult and old rats. However, rats
given AICAR, a pharmacologic AMPK activator, or rats exercise trained for 5 days on a
treadmill showed a 55% increase in phosphorylation of Thr172 of AMPKα in the young adult
rats (3 mo.) in comparison to the old rats (28 mo.). These results were further supported by
Qiang et al. (Qiang et al., 2007). At rest, phosphorylated AMPK was actually lower in the old
rats compared to young rats. AICAR was administered subcutaneously for one week to young
and old rats. The old rats showed a 63% impairment in phosphorylated AMPK levels with
AICAR, meaning there was a drastic impairment in AMPK activation in old rats compared to
young rats. More recently it was supported that in both male, and more significantly in female,
aged rats show a marked attenuation in the levels of phosphorylated AMPK in contrast to young
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rats at rest (Paturi et al., 2010). However, no form of exercise was implemented to activate
AMPK and may need to be accounted for. Therefore, endurance exercise or pharmacological
activation of AMPK may result in impaired levels of phosphorylated active AMPK in older rats
in comparison to younger rats, contradictory to the results seen in response to resistance and
overload exercise discussed earlier.
Addressing the Conflict of AMPK Activation in Aging Muscle
The research performed prior to this study shows conflicting results in AMPK activity
levels in aged rats versus young adult rats depending on the experimental procedure performed.
The current literature suggests that resistance exercise results in increased AMPK activation
levels in aged rats whereas endurance exercise results in decreased AMPK activation levels in
aged rats. A possible explanation for the discrepancy may be differences in the testing
procedures used to test AMPK activation levels or comparison between resistance versus
endurance exercise. One such example may be seen in the study performed by Reznick et al.
(Reznick et al., 2007b). Older rats run on the treadmill were run at a much lower speed for the
5 days in comparison to the young rats. This decreased intensity of endurance bout in the aged
rats may account for decreased AMPK activation levels. Therefore, a more standardized testing
procedure was needed to validate the results in response to endurance exercise.
In addition, AMPK activation is regulated by the localization and heterotrimeric
composition of the subunits. Prior to this study little research has been performed in analyzing
the differences in the localization and heterotrimeric composition of AMPK in skeletal muscle in
aged versus young adult rats. Current research has indicated that aged muscle exhibits a decrease
in AMPKα2 content but an increase in AMPKα1 content (Thomson et al., 2009; Rivas et al.,
2011). However, no current research has addressed the overall heterotrimer composition of
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AMPK and localization of AMPK in aging muscle. Localization and heterotrimeric composition
were therefore evaluated to further understand the differences reported in AMPK activation in
young adult versus old rats in response to an endurance-type exercise electrical stimulation.
Furthermore, current research on the response to AICAR treatment in aged skeletal
muscle did not address the effects of chronic AICAR treatment on endurance exercise
performance and age-related signaling pathways. We proposed that the decreased mitochondrial
biogenesis, autophagy, and fatty acid oxidation seen with aging is linked to impaired activation
of AMPK. This study addresses the effects of chronic AICAR treatment in old and young mice
following treadmill running and in vitro muscle contractions. Treadmill endurance, rate of
muscle fatigue, AMPK activation, mitochondria function, autophagy, and protein synthesis were
compared between old and young mice that receive AICAR versus a saline control treatment.
Increasing understanding of the effects of AMPK activation on the aging phenotype will further
aid in the understanding and treatment of sarcopenia to increase the quality of life of elderly
individuals.
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Objectives
The purpose of this dissertation was to clarify the controversy in the current literature
concerning the activation of AMPK in response to endurance-like exercise in aged skeletal
muscle. In addition, the following study is the first to address the nuclear localization of AMPK
after endurance-like exercise and the heterotrimer composition of AMPK in aged skeletal muscle
to understand how age-associated alterations in AMPK activation may contribute to the
misregulation of metabolic pathways seen with sarcopenia. Additionally, this dissertation
addresses the known beneficial effects that have been observed with chronic AICAR treatment in
aged skeletal muscle and how activation of AMPK may improve the aging phenotype.
The specific purpose in Chapter 2 was to determine the effect of aging on the level of
AMPK activation and heterotrimer composition in skeletal muscle after an endurance-like
muscle contraction using electrical stimulation in rats. We hypothesized:
1)

AMPK activation levels would be attenuated in the aged skeletal muscle in
contrast to the young adult skeletal muscle in response to endurance-like
muscle contractions

2)

Aged skeletal muscle would have decreased levels of the α2, β1, and γ1
isoforms and increased levels of γ2 and γ3 compared to young skeletal muscle.

In Chapter 3 the purpose was to determine the effect of aging on AMPK localization in
skeletal muscle after an endurance-like muscle contraction using electrical stimulation in rats.
We hypothesized that nuclear localization of AMPK would decrease in aged skeletal muscle
after endurance-like muscle contractions.
The specific purpose in Chapter 4 was to determine the effect of chronic AICAR
treatment on contractile performance and age-related signaling pathways. This was examined in
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young adult and old mice given four weeks of AICAR treatment followed by treadmill testing
and in vitro muscle contractions. We hypothesized:
1) AMPK activation, treadmill endurance, and muscle rate of recovery would improve
and muscle fatigue would decrease with chronic AICAR treatment in aged mice in
comparison to saline treated mice.
2) Chronic AICAR treatment would increase mitochondrial gene expression and
enzyme activity, increase the expression of autophagic markers, and decrease mTOR
activation in aged mice.
Impact
This dissertation is the first to address the nuclear localization and heterotrimeric
composition of AMPK in aged skeletal muscle to understand age-related alterations of AMPK
activation in response to endurance-type muscle contractions. Furthermore, this dissertation is
the first to address the effect of chronic AICAR treatment in aged skeletal muscle.
Understanding age-associated alterations in AMPK activation and how chronic AMPK activation
through AICAR affects the aging phenotype will open new doors to understanding sarcopenia
and how to improve the metabolic misregulations associated with sarcopenia.
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CHAPTER 2: The Effects of Age and Muscle Contraction on AMPK Activity and Heterotrimer
Composition
Shalene E. Hardman, Derrick E. Hall, Alyssa J. Cabrera, Chad R. Hancock, and
David M. Thomson
Department of Physiology and Developmental Biology, Brigham Young University, Provo,
Utah, 84602
Abstract
Sarcopenia is characterized by increased skeletal muscle atrophy due in part to alterations
in muscle metabolism. AMP-activated protein kinase (AMPK) is a master regulator of skeletal
muscle metabolic pathways. Functional AMPK is a heterotrimer composed of alpha, beta and
gamma subunits. Each subunit can be represented by one of two (α1/α2, β1/β2) or three
(γ1/γ2/γ3) isoforms. Previous work has shown that overall AMPK activation with endurancetype exercise is blunted in old vs. young skeletal muscle. However, details regarding the
activation of the specific isoforms of AMPK, as well as the heterotrimeric composition of
AMPK in old skeletal muscle are unknown. Our purpose here, therefore, was to determine the
effect of old-age on 1) the activation of the α1 and α2 catalytic subunits of AMPK in skeletal
muscle by a continuous contraction bout, and 2) the heterotrimeric composition of skeletal
muscle AMPK. We studied gastrocnemius (GAST) and tibialis anterior (TA) muscles from
young adult (YA; 8 mo old) and old (O; 30 mo old) male Fischer344 x Brown Norway F1 hybrid
rats after an in situ bout of endurance-type contractions produced via electrical stimulation of the
sciatic nerve (STIM). AMPKα phosphorylation and AMPKα1 and α2 activities were unaffected
by age at rest. However, AMPKα phosphorylation and AMPKα2 protein content and activity
were lower in O vs. YA after STIM. Conversely, AMPKα1 content was greater in O vs. YA
muscle, and α1 activity increased with STIM in O but not YA muscles. AMPKγ3 concentration
and its association with AMPKα1 and α2 was lower in O vs. YA GAST. We conclude that
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activation of AMPKα1 is enhanced, while activation of α2 is suppressed immediately after
repeated skeletal muscle contractions in O vs. YA skeletal muscle. These changes are associated
with changes in the AMPK heterotrimer composition. Given the known roles of AMPK α1, α2
and γ3, this likely contributes to sarcopenia and associated muscle metabolic dysfunction.
Introduction
Sarcopenia, or age-related skeletal muscle atrophy, affects 20-50% of adults over the age
of 60 years (Berger & Doherty, 2010a) and is defined by a decline of muscle mass and strength
that leads to frailty with aging (Thompson, 1994; Janssen et al., 2002; Verdijk et al., 2010b).
Sarcopenia is associated with many alterations in skeletal muscle metabolism such as decreased
insulin sensitivity (Goodman & Ruderman, 1979), decreased fatty acid oxidation (Sial et al.,
1996; Calles-Escandón & Poehlman, 1997; Park et al., 2006), decreased muscle protein content
(Dardevet et al., 2000; Fry et al., 2011), and an increase in dysfunctional mitochondria
(Kumaran et al., 2004b; Terman et al., 2010). These metabolic disruptions may contribute to the
decreased fiber size and contractility seen with aging muscle (Lexell et al., 1988; Evans &
Campbell, 1993; Larsson et al., 1997).
AMP-activated protein kinase (AMPK) is a cellular energy sensor that acts as a master
regulator of skeletal muscle metabolic pathways including many that are affected by aging.
AMPK is activated as it becomes phosphorylated at Thr172 by the upstream kinase LKB1.
AMPK phosphorylation and activation is dependent upon an increased cellular AMP/ATP ratio.
Both nucleotides, as well as ADP, compete for binding to AMPK. AMP binding leads to AMPK
phosphorylation through a conformational shift that makes AMPK a better substrate for LKB1
(Hawley et al., 1995; Hawley et al., 1996; Scott et al., 2007; Gowans et al., 2013) and a worse
substrate for dephosphorylation by protein phosphatase 2C (Davies et al., 1995b; Marley et al.,
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1996). Binding of AMP also allosterically activates AMPK in addition to its effect on
phosphorylation (Hawley et al., 1995; Scott et al., 2004; Witczak et al., 2008a; Gowans et al.,
2013).
AMPK is a heterotrimeric protein composed of α, β, and γ subunits (Stapleton et al.,
1996; Woods et al., 1996a). The subunits of AMPK all have multiple isoforms and differences in
isoform composition affects AMPK localization and function. The α subunit contains the
catalytic domain and the site of Thr172 phosphorylation. The α subunit has two different
isoforms, α1 or α2. The β subunit serves as a scaffolding or regulatory subunit and also has two
isoforms, β1 and β2. The γ subunit contains nucleotide binding sites and determines the degree
of AMP dependence of the AMPK heterotrimer. γ2 complexes have a higher AMP sensitivity
than γ1 subunits, which have a higher AMP sensitivity than γ3 subunits (Cheung et al., 2000).
During exercise, the AMP to ATP ratio increases by way of the adenylate kinase reaction,
thereby potently activating AMPK (Hawley et al., 1995; Winder & Hardie, 1996; Hawley et al.,
2003; Dreyer et al., 2006; Jensen et al., 2007). In both mice and humans, the α2/β2/γ1 AMPK
complex is predominant. However, exercise and muscle contraction appear to primarily activate
complexes containing α2 and γ3 isoforms, although γ1 can be activated as well (Birk &
Wojtaszewski, 2006; Treebak et al., 2007). The two catalytic α isoforms have different substrate
specificity leading to regulation of different metabolic pathways (Stapleton et al., 1996). While
some redundancy between isoforms certainly exists, the α1 subunit is particularly important in
negatively regulating muscle cell size through regulation of the mTOR pathway (Mounier et al.,
2009), while the α2 subunit appears more able to localize to the nucleus than α1, presumably to
control gene transcription (Salt et al., 1998b).
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Activation of AMPK in response to endurance exercise appears to be blunted in old
skeletal muscle (Reznick et al., 2007b; Ljubicic & Hood, 2009). However, the effect of old-age
on isoform-specific activation of the catalytic α subunit (i.e. α1 vs. α2) after exercise is unknown.
Likewise, it is not known how old-age affects the heterotrimer composition of AMPK, and how
this might relate to the effect of aging on AMPK activation. Since the effects of both exercise
and AMPK activation (e.g. increased fatty acid oxidation, glucose transport, and mitochondrial
capacity) are in opposition to many effects of aging (Foretz et al., 1998b; Bergeron et al., 2001b;
Zong et al., 2002), understanding how the AMPK system is altered in aged muscle may lead to
improved strategies for combatting age-related dysfunction.
Accordingly, this study has two purposes: 1) to evaluate catalytic isoform-specific
AMPK activation in young adult and old skeletal muscle after an electrically stimulated in situ
endurance-type contraction bout, and 2) to determine whether differences in AMPK activation
could be accounted for by alterations in AMPK subunit isoform composition.
Materials and Methods
Animal Care
Experimental procedures were approved by the Institutional Animal Care and Use
Committee of Brigham Young University. All animals were housed in a temperature controlled
(20-21°C) environment with a 12hr: 12hr light-dark cycle and fed standard chow and water ad
libitum. Young adult (YA) (8 mo.; n=8) and old (O) (30 mo.; n=8) male Fischer344 x Brown
Norway (FBN) hybrid rats were used as recommended by the National Institute of Aging for
age-related research based on studies indicating that this strain has fewer detrimental pathologies
than inbred strains and 50% mortality at about 32 months of age (Lipman et al., 1996; Lushaj et
al., 2008).
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Electrical Stimulation of the Sciatic Nerve
Rats were anesthetized using vaporized isoflurane (2–3%) in supplemental oxygen
sufficient to achieve surgical anesthetic depth. Twenty minutes after anesthetization, the sciatic
nerve of the left hindlimb was isolated just proximal to the point of trifurcation. Contraction of
the hindlimb musculature was elicited by stimulating the sciatic nerve at 100 Hz for 10 min at
one 10 msec pulse per sec and 15 volts (Grass Model S48 Stimulator, Quincy, MA). During the
contraction bout, the foot was held at approximately 90°. Sciatic nerve stimulation activates both
the chronically weight-bearing plantarflexors as well as the dorsiflexors of the hindlimb,
including the gastrocnemius (GAST) and tibialis anterior (TA) muscles. GAST and TA were
removed immediately after contraction and frozen at the temperature of liquid nitrogen. Both
muscles were analyzed to allow assessment of the AMPK system in two distinct muscles with
different ambulatory functions, with the gastrocnemius being a weight-bearing muscle, while the
TA only stabilizes and dorsiflexes the ankle during ambulation. The right hindlimb was not
subjected to electrical stimulation and was removed prior to stimulation of the left hindlimb and
served as a resting control. All tissue samples were frozen between metal tongs cooled to the
temperature of liquid nitrogen and then frozen at -95°C until further analysis.
Homogenization
Muscles were pulverized on liquid nitrogen then glass-ground homogenized in 19volumes of homogenization buffer (50 mM Tris-HCl, pH 7.4; 250 mM mannitol; 50 mM NaF;
5 mM Sodium Pyrophosphate; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 50 mM Bglycerophosphate; 1 mM sodium orthovanadate; 1 mM DTT; 1 mM benzamidine; 0.1 mM
phenylmethane sulfonyl fluoride; 5 ug/ml soybean trypsin inhibitor). The raw homogenate was
freeze- thawed three times to ensure disruption of intracellular membranes and then centrifuged
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at 10,000 x g for 10 min. Supernatants were analyzed for protein content using the DC Protein
Assay (Biorad Laboratories, Hercules, CA, USA). Supernatants were stored in microcentrifuge
tubes at -95°C until further analysis.
Western Blot and Immunodetection
Homogenates were diluted in sample loading buffer (125 mM Tris HCl, pH 6.8, 20%
glycerol, 4% SDS, 5% β-mercaptoethanol, and 0.01% bromophenol blue) and then loaded on 5%
[phosphorylated ACC (pACC), total ACC (tACC)], 7.5% [phosphorylated AKT (pAKT),
phosphorylated AMPK (pAMPK), total AMPK (tAMPK), LKB1, AMPKγ3], and 10%
[AMPKα1, AMPKα2, AMPKβ1, AMPKβ2, AMPKγ1, AMPKγ2, phosphorylated ERK (pERK),
and phosphorylated p38 MAPK (p-p38)] Tris·HCl gels (Bio-Rad Criterion System, Hercules,
CA). After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF)
membranes. Membranes were stained with Ponceau S and visually inspected for equal protein
loading. Membranes were then washed with Tris-buffered saline plus 0.1% Tween-20 (TBST),
blocked with 5% non-fat dry milk in TBST for 1 hour, and probed overnight at 4°C with primary
antibody diluted in 1% bovine serum albumin (BSA) dissolved in TBST, pH 7.6.
Primary antibody manufacturers and dilutions were as follows: pAMPK (Thr172)
(#4188/#2535, 1:5000), tAMPK (#2532, 1:2000), pACC (Ser79) (#3661, 1:5000), AMPKβ1
(#4182, 1: 2000), AMPKβ2 (#4148, 1:2000), AMPKγ1 (#4187, 1:4000), pERK (Thr202/Tyr204)
(#4370, 1:2000), p-p38 (Thr180/Tyr182) (#4511, 1:2000), and pAKT (Ser473) (#4060, 1:2000)
from Cell Signaling Technology (Beverly, MA, USA); AMPKα1 (A300-507A, 1:4000),
AMPKα2 (A300-508A, 1:20000) from Bethyl Laboratories, Inc. (Montgomery, TX, USA);
AMPKγ2 (sc-20165, 1:2000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); AMPKγ3
(custom made as described previously (Durante et al., 2002), 1:2000) from Affinity Bioreagents
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(Golden, CO, USA); tACC (streptavidin-horseradish peroxidase, RPN1231V, 1:2000) from GE
Healthcare Biosciences (Pittsburgh, PA, USA); and LKB1 (#07-694, 1:5000) from Upstate (Lake
Placid, NY, USA).
Membranes were probed with the HRP-conjugated mouse anti-rabbit secondary antibody
(#211-032-171) from Jackson Immunoresearch Laboratories, Inc. (West Grove, PA, USA) or
HRP-conjugated goat anti-mouse secondary antibody (sc-2314) from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) for 1 hour at room temperature. Membranes were washed 4 x 5 min with
TBST. ECL Plus Western Blotting Detecting Solution (GE Healthcare Bio-Sciences, Piscataway,
NJ) was applied for 2 min. Chemiluminescent signals were detected with autoradiography film
and quantified using Gel-Pro Analyzer 6.0 (Media Cybernetics, Inc. Bethesda, MD) or
AlphaEase FC software (Alpha Innotech Corp., San Leandro, CA).
AMPK Activity Assay
AMPK activity of α1 and α2 subunits immunoprecipitated from GAST and TA
homogenates was measured by the incorporation of radiolabeled phosphate from ATP into
SAMS (HHMRSAMSGLHLVKRR-OH) peptide. Activity was assessed and expressed as
picomoles per gram tissue per minute, as described previously (Park et al., 2002).
Co-Immunoprecipitation
To determine the effect aging has on the heterotrimer subunit composition, 15 µg of α1 or
α2 antibody and 1ml ice cold TBS were added to about 80 µl (packed volume) of Exactacruz IP
matrix (Santa Cruz no. sc-45039) and rotated for 1 hour at 4°C. The IP matrix was pelleted by
centrifuging for 60 sec. at 13,000 x g, then washed three times with 1 ml ice cold TBS and
resuspended in 420 µl ice cold TBS. 50 µl aliquots of the resuspended matrix were transferred to
centrifuge tubes and centrifuged. After removal of the supernatant, 400 µg of GAST homogenate
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was added to the matrix-antibody pellet which then was brought up to 500 µl total volume with
ice cold homogenization buffer. Samples were rotated end-over-end overnight at 4°C. After
rotation, samples were centrifuged for 30 sec. at 10,000 x g. The supernatant was transferred to a
fresh tube and saved. The pellet was washed three times with ice cold homogenization buffer and
then resuspended in 80 µl of loading buffer and boiled for 3 min at 100°C. Samples were then
loaded onto 10% gels for western blotting and immunodetection as described previously.
Glycogen Concentration Assay
GAST tissue samples were ground into powder under liquid nitrogen. 0.5 mL cold 30%
KOH was added to 50 mg of sample and placed in a boiling water bath for 30 min. Samples were
then neutralized with 10.7 M acetic acid. 0.1 ml of sample was transferred to a 12 x 75 mm tube
containing 0.9 ml amyloglucosidase buffer (amyloglucosidase, 50 mM acetate buffer
(50 mM acetic acid, 50 mM sodium acetate), pH 4.7). Samples were incubated at 55°C for 1
hour, vortexed, and centrifuged for 10 min. 0.1 ml of sample was transferred to a cuvette
containing 0.88 ml reaction buffer (25.4 mg MgCl2, 0.4 mg dithiothreitol (DTT), 6.9 mg ATP,
7.7 mg NADP, 25 ml 100 mM Tris buffer, pH 8.8). Initial read was set at 340 nm. G6PDH/ HK
enzyme mixture (100 units GSPDH, Sigma G-6378, 50 mM Tris, 80 units/mg solid Hexokinase,
Sigma H5375, pH 7.6) was then added to each cuvette, mixed and then read for final O.D. after
15 min.
High Performance Liquid Chromatography (HPLC)
High-energy phosphate concentrations were determined by HPLC. Muscles were
pulverized at the temperature of liquid nitrogen and then homogenized in 6% perchloric acid.
Homogenates were then centrifuged at 800 rpm for 5 min to remove protein. This was followed
by neutralization of the supernatant with neutralization solution (2 N potassium hydroxide, 0.4 M
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potassium chloride, 0.4 M imidazole) to pH 7.0. Homogenates were then vortexed and
centrifuged at 800 rpm for 5 min. 120 µl of the supernatant was placed in a fresh tube,
dehydrated, and stored at −80°C. Just prior to HPLC, samples were rehydrated in 120 µl ddH2O.
Adenine nucleotides (ATP, ADP, AMP) and IMP were quantified by reverse-phase HPLC, as
described by Tullson et al. (1990) (Tullson et al., 1990). Phosphocreatine (PCr) concentrations
were measured by ion exchange HPLC as described by Wiseman et al. (1992)(Wiseman et al.,
1992). Metabolites were expressed as micromoles per gram wet weight and corrected to the total
adenine nucleotide content plus IMP of rested muscle (6.7 μmol/g wet wt) to account for fluid
shifts that occur in response to muscle contractions as previously described (Hancock et al.,
2005; Thomson et al., 2010).
Statistics
Statistical comparisons using Microsoft Excel or GraphPad Prism statistical analysis
software (GraphPad Software Inc., La Jolla, CA) were made using a student t test or repeated
measures ANOVA to determine statistical significance (p≤0.05) with Fisher’s LSD post-hoc
analysis employed where appropriate. Values are reported as means ± SE.
Results
Effects of Age on AMPK Activation and Phosphorylation
The energetic response to the contraction bout was assessed by measuring the
concentration of glycogen and high-energy phosphate metabolites in the gastrocnemius (Table
2.1). IMP and AMP were elevated at rest in O vs. YA muscles. Following STIM, there was a
significant reduction in glycogen, PCr, and ATP for both the YA and O rats. This corresponded
to an accumulation of IMP in both the YA and O rats. (O rats had a greater drop in ATP as well
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as a greater increase in IMP than YA rats.) Response to the contraction bout was further
confirmed by measuring phosphorylation of energetic stress-related mitogenic and metabolic
proteins. STIM increased phosphorylation of ERK, AKT, and p38 similarly in both the YA and
O rats (Fig. 2.1), further verifying the effectiveness of the stimulus to elicit a similar energetic
response in both age groups by the contraction bout.
AMPK activity was next assessed by determining pAMPK protein content and AMPKα1
and α2 activity. pAMPK content increased with STIM in both O and YA rats; however, the
increase in pAMPK was significantly attenuated by 63% and 75% respectively in the GAST and
TA after STIM in O rats compared to YA suggesting impaired overall activation of AMPK in O
rats in response to STIM (Figure 2.2A). The overall protein content level of total AMPK was
decreased in O vs. YA muscle (Figure 2.2B). AMPKα2 activity followed the same trend as seen
with pAMPK with increased activity after STIM in both O and YA rats; however, that increase
was attenuated by 19% and 23% respectively in the GAST and TA in O versus YA rats
(Figure 2.2D). In contrast, AMPKα1 activity increased by 30% and 38% in the GAST and TA
respectively after STIM in O rats while α1 activity was unaffected by STIM in YA rats
(Figure 2.2C).
Effects of Age on LKB1 and ACC
Protein content of LKB1 was unaffected by age (Figure 2.3A). Total protein content of
Acetyl CoA Carboxylase (ACC), a known downstream target of AMPK, was greater in aged fast
twitch muscle in comparison to YA rats (Figure 2.3C) but pACC significantly increased with
STIM in both O and YA rats (Figure 2.3B).
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Effects of Age on AMPK Subunit Isoform Protein Content
The effect of age on the AMPK system was further addressed by measuring the protein
content levels of the AMPK isoforms. AMPKα1 protein content in O versus YA muscle was
45% and 59% higher in the GAST and TA respectively (Figure 2.4A). In contrast, AMPKα2
content was attenuated by 18% in the GAST in O versus YA rats (Figure 2.4B), but not
significantly different for the TA. Protein content levels of AMPKβ1, β2, and γ1 were not
significantly different between age groups (Figure 2.5A, 2.5B, 2.6A). AMPKγ2 content in O
versus YA rats was 75% and 49% lower in the GAST and TA respectively (Figure 2.6B).
AMPKγ3 subunit isoform content in O versus YA rats was also 85% and 78% lower in the
GAST and TA respectively (Figure 2.6C).
Effects of Age on AMPK Subunit Heterotrimer Composition
Immunoprecipitation of the catalytic isoforms AMPKα1 and α2 was followed by western
blotting to detect content of the β1, β2, γ1, γ2, or γ3 subunits associated with the two alpha
subunits in the GAST homogenates. After immunoprecipitation using the AMPKα1 and α2
antibodies, the entire western blot signal for the respective alpha subunits was contained in the
pellets and not in the supernatants, indicating that the respective alpha subunits were pulled
down completely from the homogenates (data not shown). The immunoprecipitated AMPKα1
content increased by 128% in O versus YA rats, and immunoprecipitated α2 content decreased
by 33% in O vs. YA rats (Figure 2.7), consistent with AMPK content in the whole homogenates
shown in Figure 2.4.
The amount of γ1 that co-immunoprecipitated with α1 increased similarly (130%) in O
muscle, while the amount of coimmunoprecipitated γ2 was unchanged and the amount of
coimmunoprecipitated γ3 was decreased by 82% (Figure 2.7A). Decreased association of
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AMPKα1 with γ3 was verified by immunoprecipitating γ3 and then western blotting for α2 (data
not shown). This suggests a shift from α1: γ3 complexes to α1: γ1 complexes in old vs. young
muscle. The amount of β1 and β2 subunits coimmunoprecipitated with α1 did not change
significantly (Figure 2.7A). Since α1 content increased without a change in associated β subunit
content, this suggests that at least part of the increase in α1 content is not associated in the typical
heterotrimeric complex with AMPKβ subunits, which may limit the effect this has on overall
AMPKα1 activity.
The 33% drop in immunoprecipitated α2 isoform in O muscle was associated with a
similar but non-significant drop in coimmunoprecipitated γ1 content, an even greater and
significant 83% drop in coimmunoprecipitated γ3 content, and a non-significant increase in
coimmunoprecipitated γ2 content (Figure 2.7B). Taken together the disproportionate drop in γ3
vs. α2 in this case suggests a shift away from α2: γ3 complexes, likely toward α2: γ2complexes
with old age. The decline in β1 and β2 content that coimmunoprecipitated with α2 in O muscle
was similar to the decline in immunoprecipitated α2, suggesting that interaction between α2 and
the β subunits is not altered with aging (Figure 2.7B).
Discussion
The purposes of this study were to: 1) evaluate catalytic isoform-specific AMPK
activation in young adult and old skeletal muscle after an electrically stimulated in situ
endurance-type contraction bout, and 2) determine whether differences in AMPK activation
could be accounted for by alterations in AMPK subunit isoform composition. Our findings
support the results by Reznick et al. (Reznick et al., 2007a) indicating that overall AMPKα
phosphorylation and in vitro activity of AMPKα2 is attenuated with age in response to
endurance-type muscle contraction. However, we also found that AMPKα1 protein content and
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contraction-induced activity increases with age, and aging results in decreased association of the
AMPKα1 and α2 subunits with the γ3 isoform, and increased association of α1 with γ1 and α2
with γ2.
The endurance-type in situ muscle stimulation procedure for contraction of the hindlimb
musculature was identical for both the YA and O rats. The contraction bout used here was
selected because it strongly activates AMPK in healthy young muscle (Winder & Hardie, 1996).
Similar type stimulation has been shown to lead to endurance-type adaptations when performed
chronically in rabbits (Patel et al., 1998). The energetic and signaling stress elicited by the
contraction protocol used here (Table 1 and Figure 1) suggest that it is a suitable endurance
exercise model. Although we did not measure muscle force production during the stimulation
bout, ERK, Akt, and p38 phosphorylation were similar between ages, glycogen and PCr
depletion was not significantly altered by aging, and ATP depletion and IMP accumulation were
increased in the aged muscle. This strongly indicates that the impaired AMPK activation cannot
be accounted for by a decreased energetic or overall signaling stimulus in the aged muscle.
Although AMPK phosphorylation and AMPKα2 activity increased with STIM in both
YA and O rats, the increase in AMPK phosphorylation and AMPKα2 activity was attenuated in
aged compared to YA rats in response to the endurance-type muscle contraction, consistent with
findings observed after treadmill running (Reznick et al., 2007b; Ljubicic & Hood, 2009) and in
situ contractions. This hypo-activation of AMPK was associated with lower AMPKα2 and total
AMPKα protein expression. AMPKα2 is the predominant isoform expressed in skeletal muscle
(Stapleton et al., 1996) and should therefore closely reflect the total AMPK protein content.
Altered isoform expression of the regulatory γ subunit likely contributed as well to the
impaired activation of AMPKα2 with contraction. While protein expression of the regulatory β
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subunit isoforms was not altered with age, the γ2 and γ3 isoform protein content was decreased
in O muscles, consistent with findings in aged human muscle (Mortensen et al., 2009).
Furthermore, the association of AMPKα2 with AMPKγ2 increased while its association with
AMPKγ3 decreased. Since AMPKγ3 is the predominant isoform activated in response to
exercise, particularly as a α2β2γ3 heterotrimer (Yu et al., 2004; Birk & Wojtaszewski, 2006),
this decreased α2/γ3 association in aged muscle likely contributed to the impaired activation of
AMPK with contraction. The AMPKα2 and γ3 isoforms are predominantly expressed in fasttwitch glycolytic muscle (Mahlapuu et al., 2004; Yu et al., 2004). Previous research has reported
that aging muscle atrophy is primarily accounted for by a reduction in fast-twitch muscle (Lexell
et al., 1983; Holloszy et al., 1991; Lexell, 1995). It is not surprising therefore that a reduction in
fast-twitch muscle in aged muscle would result in decreased content of the AMPKγ3 and α2
isoforms (Chen et al., 1999; Putman et al., 2007).
Given AMPK’s well-defined roles in muscle, the decreased content and activity of
AMPKα2 may contribute to many of the dysfunctional characteristics of aging skeletal muscle.
Age-related muscle dysfunction is thought to result from many factors including impaired
mitochondrial biogenesis and turnover, decreased autophagy, excessive inflammation and
enhanced ROS production. AMPK, on the other hand, stimulates mitochondrial biogenesis
(Winder et al., 2000; Bergeron et al., 2001a; Zong et al., 2002) and autophagy (Sanchez et al.,
2012), while it reduces pro-inflammatory signaling (Green et al., 2011) and ROS production
(Irrcher et al., 2009).
In contrast to the α2 isoform, we observed increased activation of AMPKα1 in O muscle
after the contraction bout. Likewise, AMPKα1 content was higher in O vs. YA muscles, which is
consistent with previous reports from our (Thomson et al., 2009) and other’s laboratories (Rivas
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et al., 2011). Its hyperactivation by contraction was also likely mediated by a decrease in its
association with the γ3 subunit, and an increase in its association with the γ1 subunit since α1
heterotrimers containing γ2 or γ3 are not activated by muscle contraction (Treebak et al., 2014).
We had not expected any association of the α1 isoform with γ3 based on previous data from mice
showing that immunoprecipitated AMPKγ3 only associates with the α2 isoform (Mahlapuu et
al., 2004; Treebak et al., 2009). We verified our results by immunoprecipitating AMPKγ3 and
then western blotting for AMPKα1, which confirmed an association between those subunits in
skeletal muscle. This discrepancy in results is likely due to species differences, since our
experiment was performed in rat muscle, while the conflicting data was in mouse muscle. This is
supported by the findings of Cheung et al (Cheung et al., 2000) who demonstrated that AMPKγ
isolated from rat liver can associate with either α subunit.
As was the case for the impaired activation of AMPKα2, the elevated AMPKα1 activity
in old muscle after contraction may have important clinical significance. AMPKα1 has been
shown to play an isoform-specific role in inhibiting the mTOR pathway and protein synthesis in
skeletal muscle (Mounier et al., 2009; Mounier et al., 2011). Thus, this could contribute to the
deficit in contraction-induced activation of mTOR and protein synthesis observed with old age
(Parkington et al., 2004; Thomson & Gordon, 2006), and, over time, result in an imbalance in
protein turnover that may contribute to sarcopenia.
Although our findings clearly indicate that AMPK composition and activity are altered in
aged sarcopenic muscle, the functional consequence of these alterations in the AMPK system
remain unclear. The phosphorylation of ACC by AMPK is considered to be a reliable indicator
of overall in vivo AMPK activity (Gowans et al., 2013) and is important because the
phosphorylation of AMPK as measured by western blot and the AMPK activity assay do not

26

reflect the in vivo allosteric activation of AMPK by an increased ratio of AMP/ATP. ACC
phosphorylation after contractions was not subdued in aged muscle, as would be expected given
the decreased AMPK phosphorylation and α2 activity, and in fact was slightly elevated in O vs.
YA TA muscles. One possibility suggested by this finding is that the functional in vivo activity
of AMPK toward ACC was not impaired in the aged muscle. This might be due, at least in part,
to the fact that ATP content dropped more and IMP content (reflective of free AMP content)
increased more in O vs. YA muscles after contractions, indicating that the AMP/ATP ratio was
greater in the old muscles after contraction. This could result in greater allosteric activation of
the phosphorylated AMPK in the old muscles, offsetting the decreased level of total
phosphorylated AMPK. Alternatively, there is evidence that alternative exercise-inducible ACC
kinases other than AMPK exist (Dzamko et al., 2008), which could likewise compensate for
decreased AMPK activity. Furthermore, the increased amount of total ACC protein content in
the O muscles may also have contributed as well by providing an increased mass of substrate for
AMPK to act upon. Our results in this regard conflict with those of Reznick et al. who observed
decreased phosphorylation of ACC in old muscles after treadmill exercise along with decreased
AMPK phosphorylation. This difference is likely due to the differing contraction models used in
the studies. Clearly, further work will need to be done to clarify the control of ACC
phosphorylation by AMPK and perhaps other kinases during exercise.
Despite the differences in AMPK subunit expression and heterotrimer composition in the
aged muscle, no differences were found in AMPK activity between YA and O resting,
unstimulated muscles. This is consistent with previous findings in rodent (Ljubicic & Hood,
2009; Thomson et al., 2009)and human (Drummond et al., 2008) muscle, and makes sense given
the broad view of AMPK as a stress-sensing system. The differences in AMPK activation that
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we observed occurred after relatively intense contractions. This begs the question, then, of how
altered AMPK signaling might play a role in age-related muscle dysfunction in individuals who
spend little to no time engaged in intense physical activity. We propose that the altered AMPK
signaling that we observe in aged muscle may contribute to sarcopenia and its associated
metabolic disruption in the following manner. As an individual engages in activities of daily
living, an energetic stress is applied to the activated muscle fibers. In old fibers, AMPKα1 is
activated earlier and to a greater degree than in young muscle, leading to impaired anabolic
signaling consistent with the findings of Mounier et al. (Mounier et al., 2009) described above.
At the same time, AMPKα2 activation is suppressed, contributing to the many metabolic
disruptions associated with sarcopenia. Validation of this hypothesis will require continued
research.
In conclusion, we found that 1) activation of AMPKα2 immediately after a continuous
bout of muscle contractions is attenuated but AMPKα1 activation is enhanced in aged skeletal
muscle, and 2) AMPK γ subunit isoform expression and association with the α subunits is altered
in a manner consistent with both the decreased activation of AMPKα2 and α1 with stimulation.
Based on current understanding of AMPK actions in skeletal muscle, these alterations in AMPK
activity in old muscle may contribute to muscle dysfunction in sarcopenia, and therapies
designed to reverse these changes would be expected to improve the aging skeletal muscle
phenotype.
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Table 2.1: High Energy Phosphate Concentrations in Gastrocnemius Muscles
_________YA_________
__________O__________
REST
STIM
REST
STIM
Glycogen
8.87 ± 0.41
4.28 ± 0.64a
8.80 ± 0.54
6.54 ± 0.66a
ATP
5.37 ± 0.03
4.22 ± 0.17a
4.63 ± 0.33b
3.69 ± 0.25ab
ADP
0.57 ± 0.01
0.57 ± 0.09
0.55 ± 0.01
0.44 ± 0.02
b
AMP
0.023 ± 0.002
0.029 ± 0.005
0.048 ± 0.009
0.030 ± 0.003
IMP
0.72 ± 0.03
2.02 ± 0.22a
1.45 ± 0.33b
2.51 ± 0.27ab
a
PCr
25.04 ± 1.10
13.32 ± 2.48
22.46 ± 0.82
12.27 ± 1.52a
High-energy phosphates (µ mol/g wet wt) n=5-8. Glycogen (mg glycogen/ g tissue wt) n=8.
a = significant difference from corresponding REST muscle; b = significant difference from
corresponding condition in the YA muscle (p < 0.05).
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Table 2.2: Summary of AMPK Heterotrimer Modifications in Aging Skeletal Muscle
Protein
Association with
Association with
Content
AMPKα1
AMPKα2
α1
↑
N/A
N/A
α2
↓
N/A
N/A
β1
↓
β2
γ1
↑
γ2
↓
γ3
↓
↓
↓
Symbols indicate the change in content in comparison to the YA rats. (↑) indicates an increase;
(↓) indicates a decrease; (-) indicates no change; (N/A) not applicable.
Isoform
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A

YR YS OR OS
~ 44/42 kD

B

~ 60 kD

YR YS OR OS

C

YR YS OR OS
~ 43 kD

Figure 2.1: Phosphorylation of Mitogen and Metabolic Proteins Increases after an Electrically
Stimulated Endurance-Type In Situ Contraction Bout (STIM) in YA and O Rats. Gastrocnemius
(GAST) muscles from young adult (YA) (8 mo.) and old (O) (30 mo.) Fisher Brown Norway
male rats were stimulated for 10 min. (1 pulse per second, 15V, 10 msec. duration) and removed
immediately after the contraction bout. Western blot analysis of GAST for (A) phosphorylated
ERK, (B) phosphorylated AKT, and (C) phosphorylated p38. N=7-8 / group. YR= YA at REST;
YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are means ± SEM. a =
significant difference from corresponding REST muscle; b = significant difference from
corresponding condition in the YA muscle (p < 0.05).
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A

B

C

D

Figure 2.2: AMPK Phosphorylation and AMPKα2 Activity Are Attenuated While AMPKα1
Activity is Increased in O vs. YA Fast-Twitched Muscles. Western blotting analysis of GAST
and tibialis anterior (TA) for (A) phosphorylated AMPK and (B) total AMPK. Activity assay of
(C) AMPKα1 and (D) AMPKα2. N=8 / group. YR= YA at REST; YS= YA with STIM; OR= O
at REST; OS= O with STIM. Values are means ± SEM. a = significant difference from
corresponding REST muscle; b = significant difference from corresponding condition in the YA
muscle (p < 0.05).
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A

~ 60 kD

YA

O YA O

YA

O YA O

B

~ 280 kD

YR YS OR OS

YR YS OR OS

YR YS OR OS

YR YS OR OS

C

~ 280 kD

Figure 2.3: LKB1 Content and ACC Response to STIM are Unaffected by Age. Western blotting
analysis of GAST and TA for (A) LKB1, (B) phosphorylated ACC, (C) total ACC. N=7-8 /
group. YR= YA at REST; YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are
means ± SEM. a = significant difference from corresponding REST muscle; b = significant
difference from corresponding condition in the YA muscle (p < 0.05).
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A

~ 63 kD

YA

O YA O

YA

O YA O

YA

O YA O

YA

O YA O

B

~ 63 kD

Figure 2.4: AMPKα1 Protein Content is Increased in O vs. YA Fast Twitch Muscle while
AMPKα2 Content is Decreased. Western blotting analysis of GAST and TA for (A) AMPKα1
and (B) AMPKα2. N=8 / group. YR= YA at REST; YS= YA with STIM; OR= O at REST; OS=
O with STIM. Values are means ± SEM. a = significant difference from YA (p < 0.05).
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A

~ 38 kD

YA

O YA O

YA

O YA O

YA

O YA O

YA

O YA O

B

~ 30 kD

Figure 2.5: AMPKβ1 and β2 Protein Content are Unchanged in O vs. YA Fast Twitch Muscle.
Western blotting analysis of GAST and TA for (A) AMPKβ1 and (B) AMPKβ2. N=8 / group.
YR= YA at REST; YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are means
± SEM.
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A

~ 37 kD

YA

O YA O

YA

O YA O

YA

O YA O

YA

O YA O

B

~ 63-75 kD

C

YA

O YA O

YA

O YA O

~ 54 kD

Figure 2.6: AMPKγ2 and γ3 Protein Content are Decreased in O vs. YA Rats. Western blotting
analysis of GAST and TA for (A) AMPKγ1, (B) AMPKγ2 and (C) AMPKγ3. N=8 / group. YR=
YA at REST; YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are means ±
SEM. a = significant difference from YA (p < 0.05).
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γ2
γ3

B
YA O YA O
α2
β1
β2
γ1
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Figure 2.7: Association of the AMPKα1 and α2 Isoform with the Regulatory Isoforms is Altered
in Aged Rats. Immunoprecipitation (IP) of the catalytic AMPKα1 or α2 isoform from GAST was
followed by western blotting of the non-catalytic subunits to determine content. (A) IP of
AMPKα1 followed by western blotting for AMPKα1, AMPKβ1, AMPKβ2, AMPKγ1, AMPKγ2,
and AMPKγ3. (B) IP of AMPKα2 followed by western blotting for AMPKα2, AMPKβ1,
AMPKβ2, AMPKγ1, AMPKγ2, and AMPKγ3. N=7-8/group. Values are means ± SEM. a =
significant difference from YA (p < 0.05).
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CHAPTER 3: The Effects of Age and Muscle Contraction on AMPK Nuclear Localization
Shalene E. Hardman and David. M. Thomson
Department of Physiology and Developmental Biology, Brigham Young University, Provo,
Utah, 84602
Abstract
Sarcopenia is the gradual degeneration of skeletal muscle mass due to alterations in
skeletal muscle metabolism. AMP-activated protein kinase (AMPK) is a master regulator of
skeletal muscle metabolic pathways and regulates many metabolic pathways that are disrupted
with aging. AMPK regulates different metabolic pathways depending on its localization in the
cytosol or nucleus. Exercise activates AMPK and increases translocation of AMPK to the
nucleus. However, the effect that aging has on AMPK translocation is unknown. To study the
effect of age on AMPK cellular localization, we studied gastrocnemius (GAST) and tibialis
anterior (TA) muscles from YA (8 mo old) and O (30 mo old) male Fischer344 x Brown Norway
F1 hybrid rats after an in situ bout of endurance-type contractions produced via electrical
stimulation of the sciatic nerve (STIM). Muscles from the resting contralateral leg served as
controls (REST). Nuclear localization of phosphorylated AMPK was impaired in aging muscle
after STIM. Additionally, nuclear localization of AMPKα2 and AMPKγ3 were impaired in aging
muscle in response to STIM. Furthermore, AMPK and the heterotrimer isoform protein contents
were also altered in aging muscle, independent of cellular localization, with an overall decrease
in LKB1, total AMPK, phosphorylated AMPK, AMPKα2, AMPKβ2, and AMPKγ2 and an
increase in AMPKα1 and AMPKγ1. The impaired translocation of activated AMPK to the
nucleus, along with the altered content of the AMPK isoforms, may provide a mechanism for
altered regulation of AMPK-regulated metabolic pathways in aging skeletal muscle.

38

Introduction
AMP-activated protein kinase (AMPK), a metabolic regulator protein, acts in opposition
to many of the effects of aging and may provide insight into the effects of aging. AMPK is a
heterotrimeric protein composed of a catalytic α subunit along with regulatory β and γ subunits
(Davies et al., 1994; Woods et al., 1996a; Cheung et al., 2000). The α and β subunits have two
distinct isoforms referred to as α1 and α2 or β1 and β2 respectively (Salt et al., 1998b). The γ
subunit has three isoforms referred to as γ1, γ2, and γ3 (Thornton et al., 1998).
AMPK is activated in response to cellular stressors, such as exercise, which increase the
ratio of AMP (adenosine monophosphate) to ATP (adenosine triphosphate) (Winder & Hardie,
1996; Sakamoto et al., 2005; Winder et al., 2006). Increased AMP-regulated allosteric activation
of AMPK increases the nuclear localization of the AMPKα2 isoform (Salt et al., 1998a; McGee
et al., 2003). Translocation of AMPKα2 from the cytosol to the nucleus allows AMPK to
regulate gene expression (Witczak et al., 2008a). The β1 isoform is also localized to the nucleus
through myristoylation and phosphorylation (Warden et al., 2001b). The γ1 isoform further
demonstrates preferential nuclear localization compared to the other two γ isoforms (Turnley et
al., 1999a).
The exact mechanism that drives AMPK into the nucleus remains unknown. However,
the nuclear localization of Snf1, the yeast analog of AMPK, has been shown to be glucoseregulated (Vincent et al., 2001) while in mammals, AMPK localization is regulated by the MEKsignaling pathway in response to cellular stress (Kodiha et al., 2007). Additionally, the catalytic
subunit of AMPK contains highly conserved carboxy-terminal hydrophobic amino acids that
function as a nuclear export signal back into the cytoplasm (Kazgan et al., 2010). Thus, when
localized to the nucleus, AMPK may regulate cell function by altering gene expression through
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phosphorylation of transcriptional regulators such as PGC1α (Jäger et al., 2007) and PPARα/γ/δ
(Leff, 2003; Bronner et al., 2004; Narkar et al., 2008). Alternatively, when AMPK is localized to
the cytoplasm it may have direct effects on metabolism (e.g. by directly promoting fatty acid
oxidation (Foretz et al., 1998a), increasing glucose transport (Foretz et al., 1998a), autophagy
(Meley et al., 2006) and inhibiting processes that consume ATP such as lipogenesis (Foretz et
al., 1998a), protein synthesis (Bolster et al., 2002; Reiter et al., 2005) and cholesterol synthesis
(Henin et al., 1995)).
Many AMPK regulated metabolic pathways, particularly fatty acid oxidation (Coggan et
al., 1992b; Sial et al., 1996), lipogenesis (Park et al., 2006), protein synthesis (Cohn et al., 1980;
Dardevet et al., 2000), autophagy (Cuervo & Dice, 2000; Del Roso et al., 2003), and Glut4
expression (Houmard et al., 1995) (Lin et al., 1991), are altered in aged skeletal muscle. Changes
in the cellular localization of AMPK may contribute to the alterations in AMPK activation and
regulation of metabolic pathways seen in aging skeletal muscle. Accordingly, the purpose of this
study was to evaluate the cellular localization of AMPK in young adult and old skeletal muscle
after an electrically stimulated endurance-type contraction bout.
Materials and Methods
Animal Care
Experimental procedures were approved by the Institutional Animal Care and Use
Committee of Brigham Young University. All animals were housed in a temperature controlled
(20-21°C) environment with a 12h: 12h light-dark cycle and fed standard chow and water ad
libitum. Young adult (YA) (8 mo.; n=8) and old (O) (30 mo.; n=8) male Fischer344 x Brown
Norway (FBN) hybrid rats were used as recommended by the National Institute of Aging for
age-related research based on studies indicating that this strain has fewer detrimental pathologies
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than inbred strains and 50% mortality at about 32 months of age (Lipman et al., 1996; Lushaj et
al., 2008).
Electrical Stimulation of the Sciatic Nerve
Rats were anesthetized using vaporized isoflurane (2–3%) in supplemental oxygen
sufficient to achieve surgical anesthetic depth. Twenty minutes after anesthetization, the sciatic
nerve of the left hindlimb was isolated just proximal to the point of trifurcation. Contraction of
the hindlimb musculature was elicited by stimulating the sciatic nerve using HFES (100 Hz;
Grass Model S48 Stimulator, Quincy, MA) for 10 min at one 10 msec pulse per second at 15
volts (STIM). During the contraction bout, the left foot was held at approximately 90° to the
tibia. The right hindlimb was not subjected to electrical stimulation and was removed prior to
stimulation of the left hindlimb and served as a resting control (REST).
The gastrocnemius (GAST), tibialis anterior (TA), and extensor digitorum longus (EDL)
were removed immediately after contraction. The GAST was frozen between metal tongs cooled
to the temperature of liquid nitrogen and then frozen at -95ºC until further analysis. The EDL
was frozen in isopentane at the temperature of liquid nitrogen and then frozen at -95ºC until
further analysis.
Nuclear Isolation
To measure nuclear localization of AMPK, the nuclear fraction (NUC) of the right and
left GAST and TA tissue samples from FBN rats were separated from the cytosolic fraction
(CYT). Tissue samples were homogenized on a glass-on-glass homogenizer in 10 µl of lysis
buffer (10 mM NaCl, pH 7.4; 1.5 mM MgCl; 20 mM HEPES; 20% glycerol; 0.1% triton X-100;
1 mM sodium orthovanadate; 1 mM DTT; 1 mM benzamidine; 200 mM phenylmethane sulfonyl
fluoride; 5 ug/µl soybean trypsin inhibitor) per mg of tissue and placed in microcentrifuge tubes.
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Samples were then centrifuged at 5000 x g for 5 min. The supernatant was collected in a separate
tube and cleared by centrifuging at 6000 x g for 3 x 5 min and then stored at -95°C for further
testing. The pellet was washed and suspended 3 times in 500 µl lysis buffer and centrifuged at
5000 x g between each wash. The pellet was then resuspended in 3µl of lysis buffer plus NaCl
(360µl stock lysis buffer plus 49.8µl of 5 M NaCl) per mg of tissue. The pellet samples were
rotated for 2 hours at 4°C to lyse the nuclei and then centrifuged at 15,000 x g for 15 min at 4°C.
The supernatant was collected and stored at -95°C for further testing.
Western Blot and Immunodetection
Homogenates were diluted in sample loading buffer (125 mM Tris HCl, pH 6.8, 20%
glycerol, 4% SDS, 5% β-mercaptoethanol, and 0.01% bromophenol blue) and then loaded on
7.5% [phosphorylated AMPK (pAMPK), total AMPK (tAMPK), LKB1, AMPKγ3], and 10%
[Lamin B, GAPDH, AMPKα1, AMPKα2, AMPKβ1, AMPKβ2, AMPKγ1, AMPKγ2] Tris·HCl
gels (Bio-Rad Criterion System, Hercules, CA). After electrophoresis, proteins were transferred
to polyvinylidene difluoride (PVDF) membranes. Membranes were stained with Ponceau S and
visually inspected for equal protein loading. Membranes were then washed with Tris-buffered
saline plus 0.1% Tween-20 (TBST), blocked with 5% non-fat dry milk in TBST for 1 hour, and
probed overnight at 4°C with primary antibody diluted in 1% bovine serum albumin (BSA)
dissolved in TBST, pH 7.6.
Primary antibody manufacturers and dilutions were as follows: pAMPK (Thr172)
(#4188/#2535, 1:5000), tAMPK (#2532, 1:2000), AMPKβ1 (#4182, 1: 2000), AMPKβ2 (#4148,
1:2000), and AMPKγ1 (#4187, 1:4000) from Cell Signaling Technology (Beverly, MA, USA);
AMPKα1 (A300-507A, 1:4000), AMPKα2 (A300-508A, 1:20000) from Bethyl Laboratories,
Inc. (Montgomery, TX, USA); AMPKγ2 (sc-20165, 1:2000), and Lamin B (M-20) (sc-6217,
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1:1000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); AMPKγ3 (custom made as
described previously (Durante et al., 2002), 1:2000) from Affinity Bioreagents (Golden, CO,
USA); LKB1 (#07-694, 1:5000) from Upstate (Lake Placid, NY, USA); and GAPDH (MAB374,
1:200,000) from EMD Millipore (Billerica, MA, USA).
Membranes were probed with the appropriate secondary antibody [HRP-conjugated
mouse anti-rabbit (#211-032-171) from Jackson Immunoresearch Laboratories, Inc. (West
Grove, PA, USA); HRP-conjugated donkey anti-goat (sc-2020) or HRP-conjugated donkey antimouse (sc-2314) from Santa Cruz Technology] for 1 hour at room temperature. Membranes were
washed 4 x 5 min with TBST. ECL Plus Western Blotting Detecting Solution (GE Healthcare
Bio-Sciences, Piscataway, NJ) was applied for 2 min. Chemiluminescent signals were detected
with autoradiography film and quantified using Gel-Pro Analyzer 6.0 (Media Cybernetics, Inc.
Bethesda, MD) or AlphaEase FC software (Alpha Innotech Corp., San Leandro, CA).
Tissue Sectioning/Immunohistochemistry
EDL muscle samples from FBN rats frozen in isopentane following electrical stimulation
extracted during tissue harvesting were placed in a mold containing Tissue Tek® O.C.T.
compound (Ted Pella Inc., Redding, CA), covered, and then flash frozen in isopentane for
30 sec. Tissue samples were placed in aluminum foil and stored at -95°C until ready to be
sectioned. Tissues were prepared for sectioning by placing in the cryostat microtome at -21°C for
30 min prior to cutting to allow the sample to equilibrate. The tissue sample was then mounted
using O.C.T. compound and cut into 10 µm muscle sections at -21°C in cryostat microtome,
placed on glass slides, and allowed to air dry. Glass slides with samples were fixed using
acetone.
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Cellular Localization
5% Normal Goat Serum (NGS) blocking solution was applied to the FBN EDL muscle
slide samples for 30 min at room temperature and then removed. The primary antibodies
pAMPKα (Cell Signaling Technology no. 4188) and caveolin (Santa Cruz Technology no. sc5310) were diluted 1:250 (0.4 µl antibody in 100 µl 5% NGS-PBS) and then applied to the
respective slide for 60 min at room temperature and washed 3 x 5 min in 1% PBS. The
secondary antibodies Alexa Fluor® 546 goat anti-rabbit IgG (Invitrogen) and goat anti-mouse
IgA-FITC (Santa Cruz Technology no. sc-3692) were diluted 1:500 (0.2 µl antibody in 100 µl
5% NGS-PBS) and applied for 30 min in the dark at room temperature and then washed
3 x 5 min in 1% PBS. The nuclei were stained with the DAPI stain for 2 min and washed
5-10 min with PBS. A coverslip was then mounted with Fluoromount-G to capture the images
using a fluorescent microscope filter set.
Statistics
Statistical comparisons using Microsoft Excel or GraphPad Prism statistical analysis
software (GraphPad Software Inc., La Jolla, CA) were made using a student t test or repeated
measures ANOVA to determine statistical significance (p≤0.05) with Fisher’s LSD post-hoc
analysis employed where appropriate. Values are reported as means ± SE.
Results
Effect of Age on AMPK Cellular Localization
Cellular localization (CYT vs. NUC) was determined by comparing the protein content
between age (YA vs. O) and condition (REST vs. STIM). GAPDH and Lamin B were detected
to verify the enrichment of the CYT and NUC fractions (Figure 3.1). Overall, the total protein
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content of AMPK in both the CYT and NUC fractions was significantly lower in O rats
compared to YA rats (Figure 3.2B). LKB1 protein content also tended to be lower in the O
versus YA rats but results were not significant (Figure 3.2A). Additionally, for both AMPK and
LKB1, protein content was not significantly different between the CYT and NUC fractions or
with STIM in both the YA and O rats (Figure 3.2A,B).
On the other hand, phosphorylated AMPK (pAMPK) protein content was not overall
significantly different between age or condition in the GAST CYT fraction and the TA CYT and
NUC fractions. However, in the GAST NUC fraction, STIM significantly increased pAMPK
protein content in the YA and O but the increase was significantly attenuated in the aging muscle
(Figure 3.2C).
Immunohistochemistry of the EDL indicated an overall decrease in colocalization of
pAMPK with both the nuclei and muscle fibers in the O versus YA rats, indicating an overall
decrease in pAMPK in aging rats. Additionally, we were unable to detect any significant
difference in pAMPK with STIM in either the YA or O rats (Figure 3.3).
Effect of Age on the Cellular Localization of the AMPKα Catalytic Isoforms
AMPKα1 protein content in the GAST was greater in the O rats than the YA rats.
However, cellular localization was not affected by age or STIM. There was no significant
difference of AMPKα1 protein content in the TA (Figure 3.4A).
In contrast, AMPKα2 protein content in both the GAST and TA tended to be lower in the
O versus YA rats. Additionally, AMPKα2 protein content was not affected by STIM in the O
rats. However, in the TA NUC fraction of the YA rats, AMPKα2 increased significantly with
STIM (Figure 3.4B).
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Effect of Age on the Cellular Localization of the Regulatory AMPKβ Isoforms
Age and condition did not alter the CYT or NUC content of AMPKβ1 (Figure 3.5A).
However, AMPKβ2 content was significantly lower in the O versus YA rats in the GAST CYT
fraction and tended to be lower in the TA. However, in the NUC fractions of the GAST and TA,
AMPKβ2 protein content was not different between age or condition (Figure 3.5B).
Effect of Age on the Cellular Localization of the Regulatory AMPKγ Isoforms
AMPKγ1 protein content in the O rats was greater than the YA rats for the GAST CYT
fraction. Additionally, with STIM, AMPKγ1 significantly increased in the YA GAST CYT
fraction to match levels found in the O rats. However, in the CYT and NUC fractions of the TA
and the NUC fraction of the GAST, AMPKγ1 was not affected by age or condition (Figure
3.6A).
On the other hand, AMPKγ2 was significantly lower in the CYT fraction of the O rats
compared to the YA rats in both the GAST and TA but was not affected by STIM. In the NUC
fractions, age and condition did not significantly change the content of AMPKγ2 (Figure 3.6B).
Lastly, AMPKγ3 was not affected by age or condition in the CYT fraction of the GAST
or in the CYT and NUC fraction of the TA. However, in the GAST NUC fraction, AMPKγ3
significantly increased with STIM in the YA rats but not the O rats (Figure 3.6C).
Discussion
This study found that the nuclear localization of phosphorylated AMPK is attenuated in
aging rats after an electrically stimulated endurance-type contraction bout. More specifically, the
nuclear localization of AMPKα2 and AMPKγ3 are attenuated in aging muscle in response to
STIM. Furthermore, this study supports previous findings from Chapter 2 that AMPK and the
heterotrimer isoform protein content are altered in aging muscle with a decrease in protein
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content of LKB1, total AMPK, pAMPK, AMPKα2, AMPKβ2, and AMPKγ2 and an increase in
AMPKα1 and AMPKγ1.
The nuclear isolation procedure was sufficient to isolate the cytosolic and nuclear
fractions as verified by the presence of Lamin B restricted mainly to the NUC fraction and
GAPDH restricted to the CYT fraction. The predominant AMPK heterotrimeric subunit
composition activated during exercise in murine and human skeletal muscle is α2β2γ3 (Cheung
et al., 2000; Durante et al., 2002; Mahlapuu et al., 2004; Yu et al., 2004; Birk & Wojtaszewski,
2006; Steinberg et al., 2010). Activation of AMPK was previously shown to result in increased
nuclear localization of the AMPKα2 isoform (Salt et al., 1998a; McGee et al., 2003).
Furthermore, AMPKα2 is the predominant isoform expressed in skeletal muscle (Stapleton et al.,
1996) and should therefore closely reflect the phosphorylated AMPK protein content.
Consistently, we found that the nuclear protein content of pAMPK and AMPKα2 in the TA
increased in response to STIM compared to REST in the YA rats. Additionally, nuclear protein
content of AMPKγ3 in the GAST increased in response to STIM in the YA rats. The disparate
response seen between the GAST and the TA may be due to the anatomical positioning of the
two muscles along with the load naturally placed on the muscle throughout the lifespan of the
rat.
Conversely, in the O rats the nuclear protein content of pAMPK also increased in
response to STIM but was significantly attenuated in the aging muscle. However, AMPKα2 and
AMPKγ3 did not increase in response to STIM in the NUC fraction of the aging muscle. The
decreased nuclear localization of activated AMPK may contribute to many of the dysfunctional
characteristics of aging skeletal muscle. One example is through the regulation of GLUT4 by
AMPK. Activation of AMPK and translocation to the nucleus regulates the expression of
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GLUT4 (glucose transporter type 4) (Holmes et al., 1999; Holmes et al., 2005), which in turn
regulates glucose uptake. Age is associated with decreased GLUT4 expression and basal glucose
uptake (dos Santos et al., 2012). Therefore, it is likely that the decreased nuclear localization of
AMPK in aging muscle may affect the gene expression of other genes to contribute to the aging
phenotype.
We additionally found that aging skeletal muscle was associated with an altered protein
content of LKB1, AMPK, and the AMPK heterotrimer isoforms. We found an overall decrease
in the protein content of LKB1, total AMPK, pAMPK, AMPKα2, AMPKβ2, and AMPKγ2. As
stated previously, AMPKα2 is the predominant isoform expressed in skeletal muscle (Stapleton
et al., 1996). Additionally, AMPKγ2 is the predominant isoform expressed in all tissues
(Mahlapuu et al., 2004). The decrease protein content of AMPKα2 and AMPKγ2 in aging
muscle further supports the overall decrease in total AMPK and pAMPK content. This overall
decrease in content of AMPK in aging muscle may further contribute to the aging phenotype by
limiting the availability of AMPK in aging muscle to regulate metabolic pathways.
Interestingly, we also saw an increase in the cytosolic concentration of AMPKα1 and
AMPKγ1. AMPKα1 has been shown to play an isoform-specific role in inhibiting the mTOR
pathway and therefore protein synthesis in skeletal muscle (Mounier et al., 2009; Mounier et al.,
2011). The increase in content of AMPKα1 in the cytosol could contribute to the deficit in
contraction-induced activation of mTOR and protein synthesis observed with old age
(Parkington et al., 2004; Thomson & Gordon, 2006). Previously in Chapter 2 we found that in
aging muscle, AMPKα1 has an increased association with AMPKγ1. Therefore, the increased
availability and interaction between AMPKα1 and AMPKγ1 in aging muscle may compensate
for the decrease in the predominant α2β2γ3 heterotrimer composition. This change in the AMPK
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heterotrimer composition along with decreased nuclear localization may contribute to the aging
phenotype by increasing the inhibition of protein synthesis.
In conclusion, the nuclear localization of phosphorylated AMPK after an electrically
stimulated endurance-type contraction bout is attenuated in aging rat skeletal muscle. This is
correlated with an overall decrease in the protein content of LKB1, total AMPK, pAMPK,
AMPKα2, AMPKβ2, and AMPKγ2 in aging muscle. The decreases in the AMPK heterotrimer
isoforms are accompanied by an increase in the protein content of AMPKα1 and AMPKγ1 in the
aging rat muscle. These alterations in the composition and localization of AMPK in aging
muscle in response to muscle contraction may contribute to the aging phenotype by changing the
localization and therefore regulation of downstream metabolic pathways.
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Figure 3.1: Purification of the Cytosolic and Nuclear Fractions from YA and O Rat Skeletal
Muscle. Gastrocnemius (GAST) and tibialis anterior (TA) muscles from YA (8 mo.) and O (30
mo.) Fisher Brown Norway male rats were stimulated for 10 min (1 pulse per second, 15V, 10
msec duration) and removed immediately after the contraction bout. Nuclear isolation was
performed to separate the cytosolic (CYT) and nuclear (NUC) fractions. Western blot images for
GAPDH and Lamin B. N=8 / group. YR= YA at REST; YS= YA with STIM; OR= O at REST;
OS= O with STIM.

50

A

YR YS OR OS

YR YS OR OS YR YS OR OS YR YS OR OS

B

YR YS OR OS YR YS OR OS YR YS OR OS YR YS OR OS

C

YR YS OR OS YR YS OR OS YR YS OR OS YR YS OR OS

~ 60 kD

~ 63 kD

~ 63 kD

Figure 3.2: Nuclear Localization of pAMPK in Response to STIM in the GAST is Attenuated in
Aging Rat Skeletal Muscle. Western blot analysis of GAST and TA for (A) LKB1, (B) total
AMPK (C) pAMPK. N=8 / group. CYT = cytosolic fraction; NUC = nuclear fraction; YR= YA
at REST; YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are means ± SEM. a
= significant difference from corresponding REST muscle; b = significant difference from
corresponding condition in the YA muscle (p < 0.05).
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Figure 3.3: Colocalization of pAMPK in the Muscle Nuclei and Fibers is Decreased in Aging Rat
Skeletal Muscle. (A) Immunohistochemistry of the extensor digitorum longus (EDL) muscle for
pAMPK, (B) Quantitative analysis of the percent of muscle nuclei colocalized with pAMPK, (C)
Quantitative analysis of the percent of muscle fibers colocalized with pAMPK,. N=7-8 / group.
CYT = cytosolic fraction; NUC = nuclear fraction; YR= YA at REST; YS= YA with STIM;
OR= O at REST; OS= O with STIM. Values are means ± SEM. a = significant difference from
corresponding REST muscle; b = significant difference from corresponding condition in the YA
muscle (p < 0.05).
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Figure 3.4: Nuclear Localization of AMPKα2 in Response to STIM in the TA is Attenuated in
Aging Rat Skeletal Muscle. Western blotting analysis of GAST and TA for (A) AMPKα1 and
(B) AMPKα2. N=8 / group. CYT = cytosolic fraction; NUC = nuclear fraction; YR= YA at
REST; YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are means ± SEM. a =
significant difference from corresponding REST muscle; b = significant difference from
corresponding condition in the YA muscle (p < 0.05).

53

A

B

YR YS OR OS YR YS OR OS YR YS OR OS YR YS OR OS

YR YS OR OS YR YS OR OS YR YS OR OS YR YS OR OS

~ 38 kD

~ 30 kD

Figure 3.5: Nuclear Localization of AMPKβ1 and β2 are Unaffected in Aging Rat Skeletal
Muscle. Western blotting analysis of GAST and TA for (A) AMPKβ1 and (B) AMPKβ2. N=8 /
group. CYT = cytosolic fraction; NUC = nuclear fraction; YR= YA at REST; YS= YA with
STIM; OR= O at REST; OS= O with STIM. Values are means ± SEM. a = significant difference
from corresponding REST muscle; b = significant difference from corresponding condition in the
YA muscle (p < 0.05).
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Figure 3.6: Nuclear Localization of AMPKγ3 in Response to STIM in the GAST is Attenuated in
Aging Rat Skeletal Muscle. Western blotting analysis of GAST and TA for (A) AMPKγ1, (B)
AMPKγ2 and (C) AMPKγ3. N=8 / group. CYT = cytosolic fraction; NUC = nuclear fraction;
YR= YA at REST; YS= YA with STIM; OR= O at REST; OS= O with STIM. Values are means
± SEM. a = significant difference from corresponding REST muscle; b = significant difference
from corresponding condition in the YA muscle (p < 0.05).
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CHAPTER 4: The Effect of Chronic AICAR Treatment on the Aging Phenotype
Shalene E. Hardman and David M. Thomson
Department of Physiology and Developmental Biology, Brigham Young University, Provo,
Utah, 84602
Abstract
Sarcopenia is characterized by alterations in many metabolic pathways. AMP-activated
protein kinase (AMPK), a metabolic regulator, acts in opposition to many of the effects of aging
and may serve as a potential therapeutic target. Acute activation of AMPK has been shown to
increase mitochondrial content, activate autophagy, and repress protein synthesis in normal
skeletal muscle; pathways that are altered with aging. However, the effect of chronic activation
of AMPK on metabolic pathways in aging skeletal muscle has yet to be addressed. Therefore, the
purpose of this study was to assess the effect of chronic activation of AMPK in aging skeletal
muscle by administering 5’-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR)
injections for one month in YA (5 mo old) and O (23 mo old) male C57Bl/6 mice. Mice were
treadmill tested prior to and after one month of AICAR treatment. Following treatment, in vitro
muscle contractions were performed on the right extensor digitorum longus (EDL) muscle.
Chronic AICAR treatment improved the treadmill endurance in O mice and the rate of fatigue
and recovery in response to in vitro muscle contractions in YA mice. Additionally, chronic
AICAR increased citrate synthase activity, decreased SQSTM1/p62 protein content, and
decreased Myf6 protein content in both the YA and O mice. Therefore, chronic AICAR
treatment alters downstream metabolic pathways in skeletal muscle to improve the exercise
response in both YA and O mice.
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Introduction
The increased risks associated with sarcopenia, or age-related skeletal muscle atrophy,
may be attributed to alterations in skeletal muscle metabolism and function. Age-associated
impairments in skeletal muscle metabolism include an increased number of dysfunctional
mitochondria (Kumaran et al., 2004a; Terman et al., 2006b), increased fat deposition due to
decreased fat oxidation (Coggan et al., 1992a; Sial et al., 1996; Calles-Escandon & Poehlman,
1997; Park et al., 2006; Slawik & Vidal-Puig, 2006), accumulation of damaged organelles
through decreased autophagy (Pfeifer, 1978; Cuervo & Dice, 2000; Del Roso et al., 2003;
Combaret et al., 2009), and a decrease in muscle protein content (Cohn et al., 1980; Dardevet et
al., 2000; Fry et al., 2011).
Adenosine monophosphate (AMP) -activated protein kinase (AMPK), a metabolic
regulator, acts in opposition to many of the age-associated impairments in skeletal muscle
metabolism. AMPK is a heterotrimeric protein composed of a catalytic α subunit along with
regulatory β and γ subunits (Davies et al., 1994; Woods et al., 1996b; Cheung et al., 2000). Liver
kinase B1 (LKB1), a serine /threonine kinase, phosphorylates the α subunit on the threonine
(Thr) 172 residue of AMPK to activate AMPK in skeletal muscle in response to endurance
exercise (Hawley et al., 1996; Winder & Thomson, 2007). In addition, endurance exercise
creates an energy deficient state, which increases the amount of AMP in comparison to
adenosine triphosphate (ATP) (Sakamoto et al., 2005; Winder et al., 2006). AMP binds to the γ
subunit of AMPK to make AMPK a better substrate for LKB1 (Hawley et al., 1995; Hawley et
al., 1996; Scott et al., 2007) and a worse substrate for Protein phosphatase 2C (PP2C), an AMPK
phosphatase (Davies et al., 1995b; Marley et al., 1996). AMP additionally induces a
conformational change in AMPK to further induce allosteric activation of AMPK (Hawley et al.,

57

1995; Scott et al., 2004; Witczak et al., 2008a). Activation of AMPK regulates metabolic
pathways to stimulate processes that produce ATP such as fatty acid oxidation (Foretz et al.,
1998a), glucose uptake (Foretz et al., 1998a), and autophagy (Meley et al., 2006) and inhibits
processes that consume ATP such as lipogenesis (Foretz et al., 1998a), protein synthesis (Bolster
et al., 2002; Reiter et al., 2005) and cholesterol synthesis (Henin et al., 1995).
AICAR, or 5’-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, is a
pharmacological activator of AMPK. AICAR increases the accumulation of 5-amino-4imidazole-carboxamide ribotide (ZMP) in the cell in a dose-dependent manner (Sabina et al.,
1985; Sullivan et al., 1994). ZMP mimics AMP to increase AMPK activation through allosteric
activation and promotion of phosphorylation (Sullivan et al., 1994; Corton et al., 1995). AICAR
is sufficient to activate AMPK in skeletal muscle similar to activation by exercise and muscle
contraction (Merrill et al., 1997). Acute AICAR treatment in skeletal muscle increases fatty acid
oxidation (Merrill et al., 1997), glucose uptake (Merrill et al., 1997) autophagy (Sanchez et al.,
2012) and protein synthesis (Bolster et al., 2002). Furthermore, chronic AICAR treatment
increases mitochondrial gene expression and enzyme activity (Holmes et al., 1999; Winder et al.,
2000; Zhou et al., 2000; Narkar et al., 2008) and increases running endurance in young, healthy
animals (Narkar et al., 2008). Therefore, chronic AICAR treatment may be sufficient to enhance
and/or compensate for the age-related changes in metabolic regulation.
Our lab has previously addressed the effect of acute AICAR treatment on AMPK
activation in aged muscle. Acute AICAR treatment increased phosphorylation of Thr172 of
AMPK and activity of AMPKα2 one hour post-treatment in both young adult and old rat muscle
tissue (Thomson et al., 2009). However, although results were not significant, there appeared to
be a blunted response to the AICAR treatment in the old rats compared to the young adult rats.
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Reznick et al. also demonstrated that rats infused with AICAR for one hour showed an increase
in phosphorylation of AMPK and increased activity of AMPKα2 in the young adult rats (3 mo.);
whereas AMPK activity in the old rats (28 mo.) was blunted (Reznick et al., 2007b). These
findings were further supported by Qiang et al (Qiang et al., 2007). Qiang et al administered
AICAR subcutaneously for one week to young and old rats. The old rats showed a 63%
impairment in phosphorylated AMPK levels with AICAR, signifying a drastic impairment in
AMPK activation in old rats compared to young rats. Therefore, although the response is blunted
in aged muscle, AICAR treatment is sufficient to activate AMPK. However, the known effects of
chronic AICAR treatment on metabolic pathways have yet to be addressed in aging muscle. We
hypothesized that one month chronic AICAR treatment would sufficiently activate AMPK to
improve the regulation of mitochondrial biogenesis, autophagy, and protein synthesis in aged
skeletal muscle.
Materials and Methods
Animal Care
Experimental procedures were approved by the Institutional Animal Care and Use
Committee of Brigham Young University. All animals were housed in a temperature controlled
(20-21°C) environment with a 12h: 12h light-dark cycle and fed standard chow and water ad
libitum. YA (5 mo.; n=24) and O (23 mo.; n=27) male C57Bl/6 mice were used as recommended
by the National Institute of Aging for age-related research.
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AICAR injections
Acute AICAR mice were subcutaneously injected with AICAR dissolved in saline
(0.5 mg/g body weight, 50 mg AICAR/ml saline) or with an equivalent volume of saline without
AICAR. Mice were anesthetized by isoflurane inhalation (2-4% with nitrous oxide in
supplemental oxygen) sufficient to achieve surgical anesthetic depth forty minutes after the
AICAR injection. Muscle tissue samples were removed 1 hour post-injection and frozen to the
temperature of liquid nitrogen and stored at -95°C until further analysis.
Chronic AICAR mice were subcutaneously injected with AICAR dissolved in saline (up
to 0.5 mg/g body weight, 50 mg AICAR/ml saline) or with an equivalent volume of saline
without AICAR daily for 31 days. (Mice were gradually brought up to the full dosage by
injecting 0.3 mg/g body weight, 50 mg AICAR/ml saline for one week; 0.4 mg/g body weight,
50 mg AICAR/ml saline for one week; and 0.5 mg/g body weight, 50 mg AICAR/ml saline for
the remaining two weeks.)
Treadmill Test
Mice were run on a rodent treadmill prior to the start of chronic injections and one week
prior to harvest. Mice were run at a temperature of 60°F on a 7% grade at for 12 m/min for
3 min, followed by 16 m/min for 3 min, and then 20m/min until exhaustion (defined as
remaining unresponsive to prodding with a brush at the back of the treadmill for 5 consecutive
seconds). Results were compared between pre and post-injections treadmill testing.
Measurement of In Vitro Contractile Properties of the EDL
After chronic AICAR injections, mice were anesthetized by isoflurane inhalation (2-4%
with nitrous oxide in supplemental oxygen) sufficient to achieve surgical anesthetic depth. The
right EDL was removed and attached to a servomotor (300B Dual-Mode Lever System; Aurora
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Scientific, Aurora, Canada) using a 4-0 silk suture and clamp-secured to a stationary platform in
a jacketed tissue bath filled with Ringer’s solution (137 mM NaCl, 24 mM NaHCO3, 11 mM Dglucose, 5 mM KCl, 2 mM CaCl2, 1 mM NaH2PO4.H2O, 1 mM MgSO4, pH 7.4; aerated with
95% O2/CO2 at 37°C). The muscle was allowed to equilibrate to the bath for 10 min. The optimal
length was determined from a resting tension of 0.2-0.5 mN at 100 volts. Force frequency
relationship was determined using a train duration of 500 msec at 10, 20, 40, 80, 100, 150, 200,
and 250 Hz (S88X Grass Stimulator; Astro-Med, Inc., West Warwick, RI, USA) after which the
muscle was stimulated for 5 min at 150 Hz with a train frequency of 0.2/sec with a train duration
of 150 msec to determine the rate of fatigue. Acute muscle recovery was determined by five
additional stimulations after resting 5 min. Following stimulation, the EDL was frozen to the
temperature of liquid nitrogen and stored at -95°C until further analysis. The white quadricep
tissues samples were removed and frozen to the temperature of liquid nitrogen and stored at 95°C until further analysis.
Homogenization
White quadricep muscles were pulverized on liquid nitrogen then glass-ground
homogenized in 19-volumes of homogenization buffer (50 mM Tris-HCl, pH 7.4; 250 mM
mannitol; 50 mM NaF; 5 mM Sodium Pyrophosphate; 1 mM EDTA; 1 mM EGTA; 1% Triton
X-100; 50 mM B-glycerophosphate; 1 mM sodium orthovanadate; 1 mM DTT; 1 mM
benzamidine; 0.1 mM phenylmethane sulfonyl fluoride; 5 ug/ml soybean trypsin inhibitor). The
raw homogenate was freeze- thawed three times to ensure disruption of intracellular membranes
and then centrifuged at 10,000 x g for 10 min. Supernatants were analyzed for protein content
using the DC Protein Assay (Biorad Laboratories, Hercules, CA, USA). Supernatants were
stored in microcentrifuge tubes at -95°C until further analysis.
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AMPK Activity Assay
AMPK activity of the α1 and α2 subunits immunoprecipitated from acute AICAR white
quadricep homogenates was measured by the incorporation of radiolabeled phosphate from ATP
into the SAMS peptide using a scintillation counter. Immunoprecipitates were prepared by
adding rabbit anti-AMPKα1 or α2 antibody to a microcentrifuge tubes containing protein G
sepharose. 40µl of spun homogenate samples were added to the rabbit antibody and protein G
sepharose pellet, mixed overnight at 4°C and washed with ice-cold IP buffer (50 mM Tris-HCl,
150 mM NaCl, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM EDTA, 1mM EGTA, 1mM
DTT, 1 mM benzamidine, 0.1 nN PMSF, 5 µg/ml soybean trypsin inhibitor, pH 7.4) and 1 M
NaCl. The pellet was then washed with lysate assay buffer (62.5 mM Na HEPES, 62.5 mM
NaCl, 62.5 mM NaF, 6.25 mM sodium pyrophosphate, 1.25 mM EDTA, 1.25 mM EGTA, 1 mM
DTT, 1 mM benzamidine, 0.1 mM PMSF, 5 µg/ml soybean trypsin inhibitor, pH 7.4),
centrifuged, and the supernatant aspirated. The pellet was resuspended in HEPES-Brij (HB)
buffer (25 mM HEPES, 0.02% Brij, 1 mM DTT, pH 7.4) and transferred to microcentrifuge
tubes. The reaction was started by adding 15 µl of the working assay cocktail (40 mM HEPES,
0.2 mM SAMS peptide (HHMRSAMSGLHLVKRR-OH), 0.2 mM AMP, 80 mM NaCl, 8%
glycerol, 0.8 mM EDTA, 0.8 mM DTT, 5 mM MgCl2, 0.2 mM ATP, pH 7.0) at timed intervals
of 30 sec. Samples were incubated at 150 rpm in a thermomixer at 30°C for 10 min. 15 µl of
reaction mix was transferred to a quarter circle of P81 filter paper, washed five times in 1%
phosphoric acid, and then washed with ddH20 and acetone and allowed to dry. The filter paper
was then added to a vial and placed in the scintillation counter along with a blank control vial
and a positive control hot assay cocktail vial to calculate the specific activity. Activity was
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assessed and expressed as picomoles phosphate incorporated into SAMS peptide per gram tissue
per minute.
Western Blot and Immunodetection
White quadricep homogenates were diluted in sample loading buffer (125 mM Tris HCl,
pH 6.8, 20% glycerol, 4% SDS, 5% β-mercaptoethanol, and 0.01% bromophenol blue) to load
onto Tris·HCl gels (Bio-Rad Criterion System, Hercules, CA). Electrophoresis was applied for
45-55 min at 200 volts. The proteins were transferred to polyvinylidene difluoride (PVDF)
membranes, which were then probed for specific proteins via immunodetection. The antibodies
used were as follows: pACC (Ser79) (#3661), Akt (#9272), pAkt (Ser473) (#4060), AMPKα
(#2532), pAMPKα (Thr172) (#4188), Atg5 (#8540), Atg7 (#8558), Atg12 (#4180), Beclin1
(#3738), 4EB-P1 (#9644), p4EB-P1 (Thr37/46) (#2855), eEF2 (#2332), peEF2 (Thr56) (#2331),
eIF2α (#9722), peIF2α (Ser51) (#9721), LC3A (#4599), LC3B (#2775), mTOR (#2983), pRaptor
(Ser792) (#2083), S6 (#2217), pS6 (Ser235/236) (#4858), p70 S6K (#2708), p-p70 S6K
(Thr389) (#9234), STAT3 (#9139), pSTAT3 (Tyr705) (#9145), SQSTM1/p62 (#5114), Ulk1
(#4773), pUlk1 (ser555) (#5869), and pUlk1 (ser757) (#6888) from Cell Signaling Technology
(Beverly, MA, USA); LKB1 (#07-694) from Upstate (Lake Placid, NY, USA); PGC1α
(#AB3242), UCP-3 (#PA1-055) from Affinity Bioreagents (Rockford, IL, USA); Cytochrome C
(#13156), Hexokinase II (#6521), MAFbx (#33782), Myf5 (#302), Myf6 (#301), MyoD (#304)
from Santa Cruz Biotechnology (Dallas, TX, USA); Cox4 (#A6403) and Oxphos (#457999)
from Invitrogen Life Technology (Grand Island, NY, USA); and ACC (streptavidin-horseradish
peroxidase, RPN1231V) from GE Healthcare Biosciences (Pittsburgh, PA, USA).
Chemiluminescent signals from blots were analyzed using AlphaEase FC software (Alpha
Innotech Corp., San Leandro, CA) to determine relative protein levels.
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Tissue Sectioning/Immunohistochemistry
Tibialis anterior (TA) muscle samples from the chronically treated mice were extracted
during tissue harvesting and placed in a mold containing Tissue Tek® O.C.T. compound (Ted
Pella Inc., Redding, CA), covered, and then flash frozen in isopentane for 30 sec. Tissue samples
were placed in aluminum foil and stored at -95°C until ready to be sectioned. Prior to sectioning,
the samples were placed in the cryostat microtome at -21°C for 30 min to allow the samples to
equilibrate. The tissue samples were mounted using O.C.T. compound and then cut into 8 µm
muscle sections at -21°C, placed on glass slides, and allowed to air dry.
CD31 Immunofluorescence
Skeletal muscle capillarity was assessed by determining the capillary to fiber ratio on
chronically-treated muscle samples. Sectioned samples were fixed in acetone and washed in
PBS, permeabilized in 0.3% Triton X-100 in PBS for 10 min at 4°C, and blocked in 5% Normal
Goat Serum (NGS) in PBS for 30 min at room temperature (RT). After blocking, samples were
incubated for at least 1 hour at RT (or overnight at 4°C) in 1:50 dilution of CD31 primary
antibody (AbD Serotec, no. MCA2388, Raleigh, NC, USA) in 5% NGS in PBS and then washed
3 X 5 min with PBS. Samples were incubated for 30 min at RT in 1:100 dilution of secondary
antibody (cy3-conjugated goat anti-rat IgG) in the dark or an opaque plastic jar. Samples were
then washed 3 X 5 min in PBS in an opaque plastic jar. Coverslips were applied using
Fluormount and images were captured using fluorescent microscopy with the TRITC filter set
and the 20X objective. To analyze, the total number of capillaries per field were counted and
expressed as a ratio to the total number of muscle fibers per field.
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Succinate Dehydrogenase Staining
Sectioned samples from the chronically-treated mice were placed in a pre-warmed
substrate solution [sodium succinate (Sigma S2378) and nitrotetrazolium blue (Sigma N6639) in
0.2 M phosphate buffer] in a 37°C water bath. Slides were washed in distilled water 3 X 1 min,
dried and mounted with a coverslip using mounting medium. Images were captured using light
microscopy. Purple formazan precipitate is deposited at sites of mitochondria. Oxidative fibers
are darker than glycolytic to allow for the percentage of cells that are SDH-positive to be
determined.
Myosin Heavy Chain (MHC) Expression
Sectioned slides were blocked in 10% normal goat serum (NGS) (Jackson
Immunoresearch, no. 005-000-121, West Grove, PA, USA) for 60 min. A primary antibody
cocktail [MHC I (Dev. Studies Hybridoma Bank, no. BA-F8, Iowa City, Iowa, USA), MHC IIa
(Dev. Studies Hybridoma Bank, no. SC-71), and MHC IIb (Dev. Studies Hybridoma Bank, no.
BF-F3) in 10% NGS] was applied to each section for 120 min. Slides were washed in PBS 3 x 5
min. A secondary antibody cocktail [AlexaFluor 350 IgG2b (Invitrogen, no. A21140, Grand
Island, New York, USA), AlexaFluor 488 IgG1 (Invitrogen, no. A21121), and AlexaFluor 555
IgM (Invitrogen, no. A21426) in 10% NGS] was applied to each section for 60 min. Slides were
washed in PBS 3 x 5 min and visualized using a fluorescent microscope.
Citrate Synthase Activity Assay
Mitochondrial function was further assessed by performing a citrate synthase activity
assay. 0.025 ml of chronic AICAR homogenates were diluted into 1.225 ml of 100 mM Tris, pH
8.0 and vortexed gently. The following reagents were added to a 1 ml quartz cuvette: 0.60 ml of
100 mM Tris, pH 8.0; 0.10 ml of 3.0 mM Acetyl-CoA; 0.10 ml of 1.0 mM DTNB, and 0.10 ml
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of the diluted homogenate. The cuvette was mixed by inversion and placed in a
spectrophotometer at 30°C for 7 min. The change in optical density (O.D.) for 3 min at 1 min
intervals (4 readings) at 412 nm was recorded. The reaction was started by adding 0.10 ml of
5 mM oxaloacetate and mixed by inversion several times. The change in O.D. for 3 min at
1 min intervals (4 readings) was recorded. Calculations were determined by the change in O.D.
per minute and the amount of tissue in the reaction cuvette.
Statistics
Statistical comparisons using Microsoft Excel or GraphPad Prism statistical analysis
software (GraphPad Software Inc., La Jolla, CA) were made using a student t test or repeated
measures ANOVA to determine statistical significance (p≤0.05) with Fisher’s LSD post-hoc
analysis employed where appropriate. Values are reported as means ± SE.
Results
Acute AICAR Treatment Increases AMPK Activity in YA and O Mice
Acute AICAR treatment was administered to verify the activation of AMPK with the
specified AICAR dosage. Phosphorylation of AMPK (pAMPK) was increased in both the YA
and O mice compared to saline treated mice one-hour post AICAR injection (Figure 4.1A).
However, pAMPK increased by 467% in the O mice whereas the YA mice only increased by
159%. Interestingly, acute AICAR treatment increased phosphorylated Acetyl Co-A Carboxylase
(pACC) in both the YA and O mice to the same extent (Figure 4.1C). Acute AICAR did not alter
total AMPK or ACC protein content (Figure 4.1B, D).
Activation of AMPK in response to acute AICAR treatment was further assessed by
determining the activity of the catalytic subunits. AMPKα1 activity did not increase with AICAR
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treatment but AMPKα2 activity increased to a similar extent in both the YA and O mice with
AICAR compared to saline treated mice (Figure 4.2).
Chronic AICAR Treatment Alters the Body Weight of YA and O Mice, Improves the Rate of
Fatigue in YA mice, and Improves Treadmill Endurance in O Mice
Prior to AICAR treatment, YA and O mice had similar body weights (Figure 4.3A).
However, the muscle weight per body weight of the O mice was significantly less than the YA
mice (Figure 4.3B). One month chronic AICAR treatment in the YA mice increased the average
body weights compared to the saline treated YA mice by about 5% (Figure 4.3A). AICAR
treatment did not affect the O mice body weight. Therefore, the O AICAR mice weighed about
4.5% less than the YA AICAR treated mice after one month (Figure 4.3A).
Mice were treadmill tested pre- and post-treatment with AICAR or saline. YA mice
treadmill endurance time was unaffected by AICAR treatment. However, in the O mice, running
performance decreased with saline treatment but AICAR prevented the drop in performance
between pre and post treadmill running (Figure 4.3C). In vitro muscle contractions were
additionally performed to assess the rate of fatigue and recovery with AICAR treatment. AICAR
treatment increased the initial force production in both the YA and O mice (Figure 4.3D).
However, AICAR treatment did not improve the rate of fatigue or recovery of the O mice. On
the other hand, YA mice fatigued at a slower rate within 2-3 min of contraction and recovered
quicker with AICAR than their saline treated counterparts (Figure 4.3E).
Chronic AICAR Treatment does not Change AMPK Protein Content in YA and O Mice
AMPK and pAMPK protein content were assessed to determine the effect of chronic
activation of AMPK by AICAR. pAMPK and total AMPK content were not significantly
different between saline and AICAR treated YA and O mice (Figure 4.4A, B). pACC and LKB1
also were unaffected by AICAR in YA and O mice (Figure 4.4C, E). However, the protein
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content of pACC was on average about 49% greater in O mice versus YA mice regardless of
treatment (Figure 4.4C). Alternatively, AICAR treated O mice had greater total ACC protein
content than both the O saline treated mice and the YA AICAR and saline treated mice (Figure
4.4D).
Chronic AICAR Treatment Increases Citrate Synthase Activity in YA and O Mice
Mitochondrial enzyme activity and gene content was measured to assess the downstream
effects of chronic AICAR treatment in aged muscle. Citrate synthase activity significantly
increased with AICAR in both the YA and O mice (Figure 4.5A) but succinate dehydrogenase
expression was unaffected by AICAR in YA and O mice (Figure 4.5B, C). PGC1α and UCP3
protein content were also unaffected by AICAR treatment in both the YA and O mice
(Figure 4.6A, D). Cytochrome C, Cox4, and oxphos complexes I, II, III, and IV all tended to
increase with AICAR treatment in YA mice, but were not significant (Figure 4.6B, C, E).
Mitochondrial protein content was not affected by AICAR in the O mice.
Chronic AICAR Treatment does not Overall Inhibit the mTOR Pathway
The effect of chronic AICAR treatment on protein synthesis in YA and O mice was
determined by assessing the regulation of the mTOR pathway. Akt, pAkt, S6K, pS6K, pS6, 4EBP1, p4EB-P1, eIF2α, eEF2, and peEF2 were all unaffected by AICAR treatment in both the YA
and O mice (Figure 4.7A-D, F-I, K-L). However, the O mice had greater protein contents of
pAkt, pS6, p4EB-P1, and eEF2 than the YA mice (Figure 4.7B, F, H, K). On the other hand, S6
content was significantly greater with AICAR treatment than saline in both the YA and O mice
(Figure 4.7E). The protein content of S6 was also significantly greater in O mice than YA mice
for both the saline and AICAR treatments. Additionally, peIF2α content was significantly lower
in both the YA and O AICAR treated mice (Figure 4.7J).
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Chronic AICAR Treatment Decreases SQSTM1/p62 Content as an Indicator of Autophagic Flux
Autophagic proteins were measured to determine the effect chronic AICAR treatment has
on the recycling of cellular components to maintain cell survival. AICAR treatment did not
significantly alter the protein content of Beclin1, Atg5, Atg12, Atg7, MAFbx, LC3A, ULK1,
pULK1 (ser555 or ser757) (Figure 4.8A-D, F, G, J-L). However, both YA and O mice had lower
SQSTM1/p62 content with AICAR treatment than saline treated mice. Additionally,
SQSTM1/p62 protein content was lower in O versus YA saline-treated mice (Figure 4.8E).
LC3B I and II content were greater in O versus YA saline treated mice (Figure 4.8H, I). AICAR
treatment in the O mice decreased the protein content of LC3B I and II but had no effect in the
YA mice (Figure 4.8H, I). However, there was no significant difference in the ratio between LC3
II and I with AICAR versus saline in the YA and O mice (data not shown).
Chronic AICAR Treatment Decreases Myf6 but does not Alter Skeletal Muscle Fiber Type
Composition or Capillarity
The effect of chronic AICAR treatment on myogenic regulating factors was assessed by
western blotting. AICAR treatment did not alter Myf5 and MyoD protein contents, but both were
significantly greater in aged muscle than YA muscle (Figure 4.9A, C). Myf6 was also greater in
the O saline versus YA saline treated mice; however, with AICAR treatment, both the YA and O
mice had significantly less Myf6 protein content (Figure 4.9B).
Fiber type composition was determined by MHC staining of the TA muscles in both YA
and O mice. There was no significant difference in fiber type composition between YA and O
mice treated with saline or AICAR; however, AICAR treatment did tend to increase type I fiber
expression in both YA and O mice, but results were not significant (Figure 4.10).
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An increase in capillarity was assessed as a potential mechanism for the improvement in
run time and rate of fatigue. However, chronic AICAR treatment did not increase the number of
capillaries found associated with each fiber in either the YA or O muscle (Figure 4.11).
Discussion
This study supports previous results by Pagala et al. (1998) that saline treated O mice
have reduced treadmill endurance but greater resistance to fatigue with in vitro muscle
contractions than YA saline treated mice (Pagala et al., 1998). Furthermore, we found that
chronic AICAR treatment prevented a reduction in run time in aged mice to match the YA
endurance levels. Chronic AICAR treatment also improved the rate of fatigue and recovery in
YA mice to match that of the O mice. These differences may be attributed to differences between
an isolated muscle and whole body interactions (i.e. an increase in the heart size or blood flow to
increase oxygen supply to the muscle).
Verification that the AICAR dosage was effective in both the YA and O mice was
demonstrated by assessing the activation of AMPK one-hour post injection. Similar to previous
research, the acute AICAR dosage was sufficient to activate AMPK in the YA and O skeletal
muscle (Merrill et al., 1997). Additionally, AICAR treatment preferentially activated the
AMPKα2 isoform in comparison to the AMPKα1 isoform (Qiang et al., 2007; Reznick et al.,
2007b; Thomson et al., 2009). However, in contrast to previous research performed in rats
(Qiang et al., 2007; Reznick et al., 2007b; Thomson et al., 2009), we found that acute AICAR
treatment increased pAMPK content to a greater extent in the O mice compared to the YA mice.
The use of mice instead of rats in this study may account for the difference seen with AICAR as
has been reported in vasculature from mice by Lesniewski et al. (Lesniewski et al., 2012).
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Alternatively, chronic AICAR injections did not alter the pAMPK or total AMPK protein
content in either the YA or O mice. AICAR injections were stopped one day prior to posttreadmill testing; therefore, pAMPK were expected to return to baseline levels. In contrast to
previous studies performed where pACC was lower in O rats (Qiang et al., 2007), we found that
pACC protein content was higher in O saline treated mice compared to YA saline treated mice.
Previous research has also indicated that chronic AICAR treatment decreases ACC activity
(Winder et al., 2000) but in the current study western blotting indicated no difference in the
protein content of pACC between saline and AICAR treated YA and O mice. Similar to previous
research, total ACC content was not different between YA and O saline treated mice (Qiang et
al., 2007). Unexpectedly, chronic AICAR treatment significantly increased the protein content
of total ACC in aged mice but not YA mice. Acute AICAR promotes fatty acid oxidation
(Merrill et al., 1997) but the increase in total ACC without the increase in phosphorylated ACC
with chronic AICAR treatment may actually suggest an increase in fatty acid biosynthesis in the
aged mice (Davis et al., 2000). The increase in total ACC with chronic AICAR further suggests
that AICAR regulates the transcription of ACC in skeletal muscle, similar to that seen in cardiac
muscle (Adam et al., 2010).
As noted previously, chronic AICAR treatment prevented a reduction in overall run time
in aged mice compared to their saline-treated counterparts to match the YA endurance levels.
Additionally, AICAR treatment improved the maximum force per muscle mass generated with in
vitro muscle contractions in both the YA and O mice. However, AICAR treatment only
improved the rate of fatigue and recovery with in vitro contractions in the YA mice not the O
mice. We hypothesized that the improvements seen between the YA and O mice may be due to
alterations in metabolic pathways regulated by AMPK.
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It has previously been shown that chronic AICAR treatment increases mitochondrial
enzyme content and activity (Winder et al., 2000; Bergeron et al., 2001b; Suwa et al., 2003). In
contrast, aging is associated with impaired mitochondrial function (Kumaran et al., 2004a;
Terman et al., 2010). Therefore, it was hypothesized that chronic AICAR treatment would
improve mitochondrial activity and therefore contribute to the improved treadmill endurance and
rate of fatigue in the YA and O mice. As expected, chronic AICAR treatment increased citrate
synthase activity in both the YA and O mice, suggesting improved mitochondrial activity with
AICAR treatment. Conversely, succinate dehydrogenase expression was unaffected by AICAR
treatment or age. Additionally, the protein content of PGC1α, cytochrome C, Cox4, UCP3, and
the oxidative phosphorylation proteins were not significantly increased with AICAR treatment.
However, there was an increasing trend in cytochrome C, Cox4, and complex II, III, and IV of
the oxidative phosphorylation proteins with AICAR treatment in the YA mice but not the O
mice. Therefore, chronic AICAR increased citrate synthase activity in both the YA and O mice
and may tend to increase other mitochondrial enzymes in the YA mice but not the O mice. These
differences in the mitochondria of YA mice but not the O mice may contribute to the improved
rate of fatigue and recovery of the isolated YA EDL muscle that was not seen in the O mice.
However, these results do not explain the overall improvement in treadmill endurance seen with
the O mice.
One proposed mechanism for the differences was that while AICAR may not increase
mitochondrial content and activity in the aging skeletal muscle, it may increase the rate of
turnover of dysfunctional mitochondria to improve treadmill endurance. The impaired
mitochondrial function seen with aging may be attributed to a reduction in autophagy and
therefore a reduction in the removal of damaged organelles (Pfeifer, 1978; Cuervo & Dice, 2000;
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Del Roso et al., 2003; Combaret et al., 2009). Alternatively, activation of AMPK is known to
increase the rate of autophagy in skeletal muscle cells (Meley et al., 2006; Sanchez et al., 2012).
Therefore, we hypothesized that chronic AICAR activation would increase the rate of autophagy
and improve endurance by removing dysfunctional mitochondria. Contrary to our hypothesis,
average autophagy levels in the O mice were not significantly lower in the YA mice. In fact,
LC3BI and II, two of the primary markers of autophagosome formation (Karim et al., 2007;
Tanida et al., 2008), were actually greater in the aged mice than the YA mice with saline
treatment. Chronic AICAR treatment in the aged mice instead lowered the levels of both LC3BI
and II to match those found in the YA mice. A decrease in LC3BI should indicate an increase in
autophagy but a decrease in LC3BII should be indicative of decreased autophagy (Kabeya et al.,
2000; Tanida et al., 2008; Barth et al., 2010). These results are therefore conflicting concerning
the rate of autophagy with chronic AICAR treatment in the aged rats. However, LC3BII is also
degraded by the lysosome, making LC3BII a difficult marker to interpret and not always the best
indicator of autophagy (Mizushima & Yoshimori, 2007). Therefore, LC3BII and LC3BI may not
be the best indicators of autophagy.
Another common marker used to measure autophagy is SQSTM1/p62. Protein content of
SQSTM1/p62 decreased with chronic AICAR treatment in both the YA and O rats.
SQSTM1/p62 interacts with ubiquitin to tag the autophagic vesicle for degradation. Increased
rates of autophagy result in a decrease in content of SQSTM1/p62 due to degradation of the
autophagic vesicle (Mizushima & Yoshimori, 2007). Therefore, although the other measured
proteins involved in autophagy were not affected, there does appear to be an increase in
autophagic vesicle degradation in YA and O mice which would indicate an increase in
autophagic flux with chronic AICAR treatment. Therefore, the effect of chronic AICAR
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treatment on autophagic flux and the removal of damaged organelles to improve cellular
metabolism and efficiency are inconclusive, but suggests a possible increase in autophagy.
Chronic activation of AMPK with AICAR may further contribute to the changes seen in
YA and O mice through the regulation of protein synthesis and muscle hypertrophy by the
mTOR pathway. Previous research has indicated that the mTOR pathway is upregulated in aged
skeletal muscle as an attempt to maintain the loss of muscle mass associated with sarcopenia
(Kimball et al., 2004). Inhibition of mTOR in aging muscle has been shown to improve the agerelated decline in spontaneous activity levels and the aging phenotype (Harrison et al., 2009;
Wilkinson et al., 2012). AICAR is a known inhibitor of the mTOR pathway in skeletal muscle
(Bolster et al., 2002). Therefore, we hypothesized that chronic AICAR treatment may improve
the aged mice endurance activity levels through inhibition of the mTOR pathway. In support of
this, the current study supports previous findings that some proteins involved in the mTOR
pathway are upregulated in the O saline mice compared to the YA saline mice (Kimball et al.,
2004; Parkington et al., 2004). Namely, pAKT, S6, pS6, p4EB-P1, and eEF2, had a higher
protein content in the O versus YA mice. This increase in the protein content of some proteins
involved in the mTOR pathway may serve as a compensatory mechanism to counterbalance the
skeletal muscle atrophy associated with aging. In addition to the mTOR pathway proteins and in
support of previous research (Musarò et al., 1995), we further found that the myogenic factors
myf5, myf6, and myoD were elevated in the aged muscle compared to the YA muscle, again
suggesting a compensatory mechanism to counteract the increasing cell death in aging muscle.
However, contrary to our hypothesis, there was no overall inhibition of the mTOR
pathway as would have been expected with chronic AICAR treatment in either the YA or the O
mice. In contrast, chronic AICAR treatment increased the protein content of S6 in the YA and O
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mice, which would suggest greater regulation of protein translation and cell growth; however,
AICAR did not change the levels of pS6. Additionally, chronic AICAR treatment decreased the
protein content of peIF2α, suggesting a potential increase in translation initiation in both the YA
and O mice. The small effect that chronic AICAR treatment has on the mTOR pathway may be
due to the short-term effect of AMPK activation on mTOR. Many studies have shown that
AICAR inhibits the mTOR pathway for about 20-30 min but within 40-60 min mTOR signaling
is no longer affected (Thomson & Gordon, 2006; Williamson et al., 2006). Therefore, chronic
AICAR may not inhibit the mTOR pathway but may instead lead to activation of mTOR-related
proteins and protein synthesis. Alternatively, chronic AICAR decreased the protein content of
Myf6, which may suggest a decrease in muscle regeneration with AICAR treatment (Braun et
al., 1990).
In addition to muscle growth and differentiation, we addressed the effect of chronic
AICAR treatment on fiber-type composition. Previous research has indicated that chronic
AICAR treatment has no effect on muscle fiber-type composition (Bamford et al., 2003; Putman
et al., 2007). Likewise, we found that chronic AICAR treatment did not alter the muscle fiber
type composition or capillarity. However previous studies have also indicated that in mouse EDL
muscles, aged mice have a preferential reduction in type II fibers (Lexell et al., 1983) and
therefore an increased percentage of slow oxidative fibers (Alnaqeeb & Goldspink, 1987). Suwa
et al. (1985) also found that chronic AICAR treatment decreased the amount of type IIB
glycolytic fibers and therefore increased the percentage of IIX oxidative fibers in rat EDL
muscles (Suwa et al., 2003). Likewise, we found that there did appear to be an increasing trend
in the oxidative type I fibers with AICAR treatment compared to saline treatment, although the
results were not significant. An increase in slow oxidative fibers in the aged mice may improve
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the response to AICAR. Slow oxidative fibers have a higher percentage of the AMPKα2 subunit
than the AMPKα1 subunit (Putman et al., 2007). As discussed previously, AICAR preferentially
activates the AMPKα2 subunit. The increase in the AMPKα2 with AICAR in aged muscle with
the change in fiber type composition may contribute to the increased endurance with treadmill
running in the aged mice but cannot completely account for the overall improvements seen in the
aging muscle.
Future Directions
Although chronic AICAR slightly changed the protein content of a few metabolic
proteins, we cannot conclusively say that chronic AICAR treatment significantly impacted the
age-related signaling pathways of mitochondrial biogenesis, autophagy, or protein synthesis.
However, the YA mice did have a decrease in the rate of fatigue and improved recovery with
AICAR treatment and the O mice had improved treadmill endurance. Therefore, other metabolic
pathways not assessed in this study may be influencing the improved endurance. In addition,
differences in the YA and O mice with AICAR treatment may be due to the difference between
evaluating the endurance of a single muscle versus whole body interactions. Chronic AICAR
treatments had a more robust improvement in mitochondrial activity and gene expression in the
YA mice that may have improved the rate of fatigue and recovery of a single muscle in isolation.
However, the improvement in treadmill endurance in the O mice may be regulated by
interactions between many factors. Although improvements in mitochondrial biogenesis,
autophagy, and protein synthesis were not overall significantly affected by chronic AICAR
treatment, there may be other tissues or factors affected besides skeletal muscle (i.e. an increase
in the heart size or blood flow to increase oxygen supply to the muscle) to improve the treadmill
endurance in the aged muscle.
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Additionally, other signaling pathways may be affected by the chronic AICAR treatment.
One potential target is hexokinase II to increase the glycolytic potential of the YA and O mice
muscles. Previous research has indicated that AICAR treatment increases the protein content of
Hexokinase II (Holmes et al., 1999; Ojuka et al., 2000; Winder et al., 2000). Similarly, we found
that Hexokinase II protein content increased with AICAR treatment in both the YA and O mice
(See Supplemental Figure 4.1A). The combination of increased glycolytic potential and
mitochondrial activity may decrease the rate of fatigue and improve endurance capabilities.
Another potential pathway that may contribute to the improved endurance to in vitro
muscle contractions and treadmill running may be through inflammatory pathways. Aged muscle
has an increase in low-grade inflammation (Salminen et al., 2008; de Magalhães et al., 2009).
Alternatively, we found that chronic AICAR treatment significantly decreased phosphorylated
STAT3 protein content in both the YA and O mice without changing the total STAT3 protein
content (See Supplemental Figure 4.1B, C). This may indicate a decrease in inflammation with
chronic AICAR treatment but will require further investigation.
In conclusion, chronic AICAR treatment improved the treadmill endurance in O mice and
the rate of fatigue and recovery in response to in vitro muscle contractions in YA mice.
However, the exact mechanism for the improvements remain unknown. Chronic AICAR
increased citrate synthase activity in both the YA and O mice and tended to increase
mitochondrial gene content in the YA mice. Additionally, chronic AICAR treatment decreased
SQSTM1/p62 and Myf6 protein content in both the YA and O mice, suggesting increased
autophagy and decreased muscle regeneration with treatment. However, the differences seen
with AICAR treatment on treadmill endurance and rate of fatigue cannot conclusively be
attributed to changes in protein synthesis, autophagy, fiber type distribution, or muscle
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differentiation. Therefore, the improvements in endurance may be due to improvements in
factors other than skeletal muscle energetics (e.g. cardiac function, blood supply, etc.). Aging
muscle may have been impacted more by the chronic AICAR treatment than YA muscle due to
greater deterioration in whole body energetics allowing for a greater range of improvement with
treadmill endurance. Alternatively, improvements in isolated skeletal muscle energetics
improved the rate of fatigue and recovery in the YA skeletal muscle but not aged muscle. This
may primarily be due to the improvements in mitochondrial protein expression and activity that
was seen in the YA muscle versus the O muscle with chronic AICAR treatment. Therefore,
chronic AICAR treatment can regulate metabolic pathways that are altered as a result of aging to
improve the exercise capacity in response to treadmill running and in vitro muscle contractions.
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Figure 4.1: Acute AICAR Injections Increase Phosphorylation of AMPK and ACC. White
quadricep (WQ) muscles from YA (5 mo.) and O (23 mo.) male C57Bl/6 mice were
subcutaneously injected with AICAR dissolved in saline (0.5 mg/g body weight, 50 mg
AICAR/ml saline) or with an equivalent volume of saline without AICAR. Western blot analysis
of WQ for (A) pAMPK, (B) total AMPK, (C) pACC, and (D) total ACC. N=4 / group. YS= YA
saline treated; YA= YA AICAR treated; OS= O saline treated; OA= O AICAR treated. Values
are means ± SEM. a = significant difference from corresponding saline treated muscle;
b = significant difference from corresponding condition in the YA muscle (p < 0.05).

79

A

B

Figure 4.2: Acute AICAR Injections Increase AMPKα2 Activity but not AMPKα1. Activity
assay of the WQ for (A) AMPKα1 and (B) AMPKα2. N=4 / group. Values are means ± SEM.
a = significant difference from corresponding saline treated muscle (p < 0.05).
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Figure 4.3: Chronic AICAR Injections Increase Body Weight in YA and O Mice, Improve
Treadmill Endurance in O Mice, and Improve the Rate of Fatigue and Recovery in YA Mice. YA
and O mice were subcutaneously injected with AICAR dissolved in saline (0.5 mg/g body
weight, 50 mg AICAR/ml saline) or with an equivalent volume of saline without AICAR for 31
days. Mice were weighed and treadmill tested prior to and following injections. (A) Total body
weights, (B) muscle weight per body weight for tibialis anterior (TA) and gastrocnemius
(GAST), (C) change in run time. After injections the right extensor digitorum longus (EDL)
muscle was removed and stimulated for 5 min at 150 Hz with a train frequency of 0.2/sec with a
train duration of 150 msec to determine the rate of fatigue. (D) initial force per EDL muscle
weight. Acute muscle recovery was then determined by 5 additional stimulations after 5 min. (E)
rate of fatigue and recovery. N=9-13 / group. Values are means ± SEM. a = significant difference
from corresponding saline treated muscle; b = significant difference from corresponding
condition in the YA muscle (p < 0.05).
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Figure 4.4: Chronic AICAR Injections Increase the Protein Content of Total ACC in O Mice but
do not Alter pAMPK, Total AMPK, pACC, and LKB1 Content. Western blotting analysis of
WQ for (A) pAMPK, (B) total AMPK, (C) pACC, (D) total ACC, and (E) LKB1. N=9-13 /
group. YS= YA saline treated; YA= YA AICAR treated; OS= O saline treated; OA= O AICAR
treated. Values are means ± SEM. a = significant difference from corresponding saline treated
muscle; b = significant difference from corresponding condition in the YA muscle (p < 0.05).
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Figure 4.5: Chronic AICAR Injections Increase Citrate Synthase Activity but not SDH
Expression. Activity assay of the WQ for (A) Citrate synthase. Immunohistochemistry of the
tibialis anterior (TA) for (B) Succinate dehydrogenase (SDH) quantification and (C) SDH
images. N=9-13 / group. Values are means ± SEM. a = significant difference from corresponding
saline treated muscle (p < 0.05).
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Figure 4.6: Chronic AICAR Injections Tend to Increase Mitochondrial Protein Content in YA
but not O Mice. Western blotting analysis of WQ for (A) PGC1α, (B) Cytochrome C, (C) Cox4,
(D) UCP3, and (E) Oxphos proteins. N=9-13/ group. YS= YA saline treated; YA= YA AICAR
treated; OS= O saline treated; OA= O AICAR treated. Values are means ± SEM. (p < 0.05).
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Figure 4.7: Chronic AICAR Injections Increase S6 but Decrease peIF2α Protein Content.
Western blotting analysis of WQ for (A) Akt, (B) pAkt, (C) S6K, (D) pS6K, (E) S6, (F) pS6, (G)
4EB-P1, (H) p4EB-P1, (I) eIF2α, (J) peIF2α, (K) eEF2, and (L) peEF2. N=9-13/group. YS= YA
saline treated; YA= YA AICAR treated; OS= O saline treated; OA= O AICAR treated. Values
are means ± SEM. a = significant difference from corresponding saline treated muscle;
b = significant difference from corresponding condition in the YA muscle (p < 0.05).
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Figure 4.8: Chronic AICAR Injections Decrease SQSTM1/p62 Protein Content. Western blotting
analysis of WQ for (A) Beclin1 (B) Atg5, (C) Atg12, (D) Atg7, (E) SQSTM1/p62, (F) MAFbx,
(G) LC3A, (H) LC3BI, (I) LC3BII, (J) Ulk1, (K) pUlk1 (ser555), and (L) pUlk1 (ser757). N=913/group. YS= YA saline treated; YA= YA AICAR treated; OS= O saline treated; OA= O
AICAR treated. Values are means ± SEM. a = significant difference from corresponding saline
treated muscle; b = significant difference from corresponding condition in the YA muscle
(p < 0.05).

86

A

YS YA OS OA

~28-32 kD

B

YS YA OS OA

~27 kD

C

YS YA OS OA

~35 kD

Figure 4.9: Chronic AICAR Injections Decrease Myf6 Protein Content. Western blotting
analysis of WQ for (A) Myf5, (B) Myf6, and (C) MyoD. N=9-13/group. YS= YA saline treated;
YA= YA AICAR treated; OS= O saline treated; OA= O AICAR treated. Values are means ±
SEM. a = significant difference from corresponding saline treated muscle; b = significant
difference from corresponding condition in the YA muscle (p < 0.05).
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Figure 4.10: Chronic AICAR Injections do not Alter Myosin Heavy Chain Content.
Immunohistochemistry for myosin heavy chain (MHC) fiber type composition. N=9-13/group.
Values are means ± SEM.
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Figure 4.11: Chronic AICAR Injections do not Increase Capillarity. Immunohistochemistry for
CD31 as a marker of capillaries. N=9-13/group. Values are means ± SEM.
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Supplemental Figure 4.1: Chronic AICAR Injections Increase Hexokinase II but Decrease
pSTAT3 Protein Content. Western blot analysis in WQ for (A) Hexokinase II (B) STAT3, and
(C) pSTAT3. N=9-13/group. YS= YA saline treated; YA= YA AICAR treated; OS= O saline
treated; OA= O AICAR treated. Values are means ± SEM. a = significant difference from
corresponding saline treated muscle (p < 0.05).
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CHAPTER 5: Summary
The overall purpose of the studies described in chapters 2-4 was to better understand the
age-associated alterations in AMPK in skeletal muscle and chronic activation of AMPK as it
relates to the development of sarcopenia. Specifically, the following questions were addressed:
1) Is AMPK activation in response to endurance-like exercise attenuated in aged
skeletal muscle?
2) Does the AMPK heterotrimer composition change in aged skeletal muscle?
3) Does the nuclear localization of AMPK after endurance-like exercise change in aging
skeletal muscle?
4) Does chronic activation of AMPK improve the aging phenotype in response to
endurance-type exercise?
5) Are the known beneficial effects that have been observed with chronic AICAR
treatment on metabolic pathways found in aged skeletal muscle?
We had hypothesized that AMPK activation after endurance-like muscle contractions
would be impaired in aged skeletal muscle as a result of altered changes in the AMPK
heterotrimer composition and localization. Therefore, we further hypothesized that chronic
activation of AMPK with AICAR treatment would improve the aging phenotype. This study
found the following answers to the above-mentioned questions:
AMPK Activation is Attenuated with Endurance-Like Exercise in Aged Skeletal Muscle.
In support of our hypothesis, we found that AMPKα phosphorylation was lower in O vs.
YA rat muscles after STIM. This suggests an attenuated activation of AMPK in response to
electrical stimulation. More specifically, AMPKα2, the predominant catalytic subunit activated

91

in response to endurance-type exercise, was also lower in O vs. YA muscles with STIM.
However, AMPKα1 activity was greater in O vs. YA muscle with STIM.
Furthermore, ACC, ERK, AKT, and p38 phosphorylation increased with STIM. However,
phosphorylation, particularly ACC phosphorylation, was not lower after contractions in O vs.
YA muscles. These results suggest that while in situ AMPK activity is suppressed, in vivo
AMPK activity may not be suppressed by old-age in rat skeletal muscle.
The AMPK Heterotrimer Composition is Altered in Aging Skeletal Muscle
In support of the change in catalytic subunit activity, AMPKα2 protein content was lower
and AMPKα1 protein content was greater in O vs. YA rats after STIM. Additionally, AMPKγ2
and γ3 protein contents were lower in O vs. YA muscle. However, AMPKβ1, β2, and γ1 protein
contents were unaffected by age.
The changes in the individual isoform protein contents suggest a change in the
availability of the AMPK isoforms and therefore alterations in the AMPK heterotrimer
composition in aging skeletal muscle. In support of this, we found that association of AMPKα2
with AMPKγ2 increased while association with AMPKγ3 decreased. We also observed
decreased association of AMPKα1 with the γ3 isoform in O vs. YA muscles. However, there was
not a comparable increase in coimmunoprecipitated β1 or β2 subunits with the increase in
AMPKα1 in aging rat skeletal muscle.
AMPK Nuclear Localization after Endurance-Like Exercise is Impaired in Aging Skeletal
Muscle
In support of our hypothesis, nuclear localization of phosphorylated AMPK was impaired
in aging muscle after STIM. Additionally, nuclear localization of AMPKα2 and AMPKγ3 were
also impaired in aging muscle in response to STIM. Results also reconfirmed the alteration of the
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AMPK heterotrimer isoform protein content. Specifically, LKB1, total AMPK, phosphorylated
AMPK, AMPKα2, AMPKβ2, and AMPKγ2 protein content decreased and AMPKα1 and
AMPKγ1 protein content increased. Consequently, aging not only alters the composition and
activity of AMPK, but also the availability of AMPK to either regulate gene transcription in the
nucleus or directly interact with cytosolic targets to regulate metabolic pathways.
Chronic Activation of AMPK Improved Treadmill Endurance in Aging Skeletal Muscle and In
Vitro Muscle Contraction Endurance in Young Adult Skeletal Muscle
As we hypothesized, one month of chronic activation of AMPK with AICAR treatment
improved the treadmill endurance of O mice. Interestingly, chronic AICAR treatment did not
improve the treadmill endurance of YA mice. Conversely, chronic AICAR treatment improved
the rate of fatigue and recovery with in vitro muscle contractions in YA mice but not O mice.
Chronic AICAR Treatment does not Conclusively Alter Mitochondrial Biogenesis, Protein
Synthesis, or Autophagy in Aged Skeletal Muscle
The improvements in endurance-type exercise with chronic AICAR treatment suggest
changes in metabolic pathways. However, the improvements we saw in both the YA and O mice
cannot conclusively be attributed to changes in protein synthesis, autophagy, fiber type
distribution, or muscle differentiation. Therefore, the improvements in endurance may be due to
improvements in factors other than skeletal muscle energetics (e.g. cardiac function, blood
supply, etc.). Aging muscle may have been impacted more by the chronic AICAR treatment than
YA muscle due to greater deterioration in whole body energetics allowing for a greater range of
improvement. Alternatively, improvements in isolated skeletal muscle energetics improved the
rate of fatigue and recovery in the YA skeletal muscle but not aged muscle. This may primarily
be due to the improvements in mitochondrial protein expression and activity that was seen in the
YA muscle versus the O muscle with chronic AICAR treatment.
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Conclusion
In conclusion, the AMPK heterotrimer composition and activity is altered in aging
muscle. Additionally, chronic activation of AMPK by AICAR treatment can improve the
treadmill endurance of aging mice. These improvements with chronic AICAR suggest that the
alteration in AMPK heterotrimer composition and activation in aging muscle may contribute to
the aging phenotype by altering AMPK signaling. However, chronic AICAR treatment does not
overall significantly impact mitochondrial, mTOR, or autophagy signaling proteins in aging
muscle to account for the improvements in exercise endurance.
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